These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
¨
|
Preliminary Proxy Statement
|
¨
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
x
|
Definitive Proxy Statement
|
¨
|
Definitive Additional Materials
|
¨
|
Soliciting Material under § 240.14a-12
|
International Flavors & Fragrances Inc.
|
|
x
|
No fee required.
|
¨
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
(1) Title of each class of securities to which transaction applies:
|
|
(2) Aggregate number of securities to which transaction applies:
|
|
(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
(4) Proposed maximum aggregate value of transaction:
|
|
(5) Total fee paid:
|
|
¨
|
Fee paid previously with preliminary materials.
|
¨
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
(1) Amount Previously Paid:
|
|
(2) Form, Schedule or Registration Statement No.:
|
|
(3) Filing Party:
|
|
(4) Date Filed
|
|
![]() |
|
International Flavors & Fragrances Inc.
521 West 57th Street
New York, NY 10019
|
1.
|
Elect eleven members of the Board of Directors for a one-year term expiring at the 2017 Annual Meeting of Shareholders.
|
2.
|
Ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2016 fiscal year.
|
3.
|
Approve, on an advisory basis, the compensation of our named executive officers in 2015.
|
4.
|
Transact such other business as may properly come before the 2016 Annual Meeting and any adjournment or postponement of the 2016 Annual Meeting.
|
|
Sincerely,
|
|
![]() |
|
Andreas Fibig
|
|
Chairman and Chief Executive Officer
|
|
|
|
|
Date and Time
:
|
Monday, May 2, 2016 at 3:00 p.m. local time / 9:00 a.m. Eastern Daylight Time
|
Place
:
|
61 rue de Villiers, Neuilly-sur-Seine, France
|
Record Date
:
|
March 8, 2016
|
Voting
:
|
Each share of our common stock outstanding at the close of business on March 8, 2016 has one vote on each matter that is properly submitted for a vote at the 2016 Annual Meeting.
|
|
Matter
|
|
Board Recommendation
|
|
Page Reference
(for more details)
|
Election of Directors
|
|
FOR each Director Nominee
|
|
5
|
Ratification of Independent Registered Public Accounting Firm
|
|
FOR
|
|
25
|
Advisory Vote on Executive Compensation
|
|
FOR
|
|
50
|
|
▪
|
“Innovating Firsts” —
strengthening our position and driving differentiation in priority R&D platforms:
|
▪
|
Our Fragrance encapsulation portfolio improved double-digits on a currency neutral basis, led primarily by Fabric Care, as well as Toiletries and Home Care, which also grew double-digits.
|
▪
|
We launched four new captive and proprietary Fragrance Ingredient molecules.
|
▪
|
Sales of our Flavors sweetness and savory modulation portfolio improved strong double-digits as we added two new natural taste modulators.
|
▪
|
Proprietary Flavors delivery systems grew strong double-digits globally given the expansion into additional categories.
|
•
|
“Win Where We Compete” —
achieving a #1 or #2 market leadership position in key markets and categories, and with specific customers:
|
▪
|
We fortified our market share position in North American Flavors, one of our key markets, with our acquisition of Ottens Flavors.
|
▪
|
North American Flavors grew 11%.
|
▪
|
We continued to leverage our long-standing presence in emerging markets, which grew 5% on a currency neutral basis, led by double digit growth in the Middle East and Africa.
|
▪
|
From a category perspective, Home Care improved high single digits globally on a currency neutral basis.
|
•
|
“Become Our Customers’ Partner of Choice” —
attaining commercial excellence by providing our customers with in-depth local consumer understanding, industry-leading innovation, outstanding service and the highest quality products:
|
▪
|
We continued our commitment to sustainability and innovation, winning multiple global sustainability certifications.
|
▪
|
Our largest Flavors customer awarded us an innovation award for North America.
|
▪
|
We continued to expand our relationships with regional customers and achieved additional core list status with several key customers across both flavors and fragrances.
|
•
|
“Strengthen and Expand the Portfolio” —
pursuing value-creation through partnerships, collaborations, and acquisitions within flavors, fragrances and adjacencies:
|
▪
|
During 2015, we negotiated and closed two acquisitions that fit into our Vision 2020 strategy.
|
▪
|
Through our acquisition of Ottens Flavors in May 2015, we expanded our flavors position in North America and increased our penetration of small and mid-size customers.
|
▪
|
Our acquisition of Lucas Meyer Cosmetics expanded our ingredients offerings into the cosmetic industry thereby allowing us to build greater customer intimacy and entry into the skin care and hair care businesses.
|
(dollars in millions except earnings per share amounts)
|
|
2013
|
|
|
2014
|
|
|
2015
|
|
|||
Net Sales
|
|
|
$2,953
|
|
|
|
$3,089
|
|
|
|
$3,023
|
|
Currency Neutral Sales Growth*
|
|
5
|
%
|
|
5
|
%
|
|
5
|
%
|
|||
Diluted Net Earnings Per Share - as Reported
|
|
|
$4.29
|
|
|
|
$5.06
|
|
|
|
$5.16
|
|
Diluted Net Earnings Per Share - as Adjusted*
|
|
|
$4.46
|
|
|
|
$5.08
|
|
|
|
$5.25
|
|
Operating Profit - as Reported
|
|
|
$516
|
|
|
|
$592
|
|
|
|
$588
|
|
Operating Profit - as Adjusted*
|
|
|
$540
|
|
|
|
$601
|
|
|
|
$612
|
|
Net Cash Provided by Operations
|
|
|
$408
|
|
|
|
$518
|
|
|
|
$434
|
|
|
|
•
|
Our Board has adopted a new “proxy access” by-law that permits eligible shareholders to nominate candidates for election to our Board.
|
•
|
Our Board consists entirely of independent directors, other than our Chairman and CEO.
|
•
|
We have an independent Lead Director to facilitate and strengthen the Board’s independent oversight.
|
•
|
Our Board is elected annually. Our Board is elected via a majority voting standard in uncontested elections.
|
•
|
Our Directors are subject to term limits.
|
•
|
Our Board is diverse, bringing an appropriate balance of skills, professional experience and perspectives.
|
•
|
Our executive clawback policies allow us to recoup certain amounts in cases of accounting misstatements, financial restatements and misstatements (without regard to fault), willful misconduct or violations of Company policy that are material and detrimental to the Company, and violations of non-competition, non-solicitation, confidentiality and similar covenants.
|
•
|
We require our executives and directors to meet stock retention guidelines.
|
•
|
We do not permit short sales or hedging of our stock by our employees, officers or directors.
|
|
Page
|
Q:
|
What am I voting on?
|
A:
|
At the 2016 Annual Meeting you will be asked to vote on the following proposals. Our Board recommendation for each of these proposals is set forth below.
|
|
|
|
|
Proposal
|
|
Board
Recommendation
|
|
1.
|
To elect eleven members of the Board of Directors, each to hold office for a one-year term expiring at the 2017 Annual Meeting of Shareholders.
|
|
FOR each Director Nominee
|
|
|
|
|
2.
|
To ratify the selection of PricewaterhouseCoopers LLP (“PwC”) as our independent registered public accounting firm for the 2016 fiscal year.
|
|
FOR
|
|
|
|
|
3.
|
To approve, on an advisory basis, the compensation of our named executive officers in 2015, which we refer to as “Say on Pay.”
|
|
FOR
|
|
|
|
|
Q:
|
Who can vote?
|
A:
|
Holders of our common stock at the close of business on March 8, 2016, are entitled to vote their shares at the 2016 Annual Meeting. As of March 8, 2016, there were 79,685,747 shares of common stock issued, outstanding and entitled to vote. Each share of common stock issued and outstanding is entitled to one vote.
|
Q:
|
What constitutes a quorum, and why is a quorum required?
|
A:
|
We are required to have a quorum of shareholders present to conduct business at the meeting. The presence at the meeting, in person or by proxy, of the holders of a majority of the shares entitled to vote on the record date (39,842,875 shares) will constitute a quorum, permitting us to conduct the business of the meeting. Abstentions and broker non-votes are counted as present for purposes of determining a quorum. Shares of common stock for which we have received executed proxies will be counted for purposes of establishing a quorum at the meeting, regardless of how or whether such shares are voted on any specific proposal.
|
Q:
|
What is the difference between a “shareholder of record” and a “street name” holder?
|
A:
|
If your shares are registered directly in your name with our transfer agent, American Stock Transfer & Trust Company, you are considered a “shareholder of record” or a “registered shareholder” of those shares. In this case, your Notice of Internet Availability of Proxy Materials (“Notice”) has been sent to you directly by us.
|
Q:
|
How do I vote?
|
A:
|
If you are a shareholder of record, you may vote:
|
•
|
via Internet;
|
•
|
by telephone;
|
•
|
by mail, if you received a paper copy of the proxy materials; or
|
•
|
in person at the meeting.
|
Q:
|
What are the requirements to elect the director nominees and to approve each of the proposals in this proxy statement?
|
|
Proposal
|
|
Vote Required
|
|
|
1.
|
Election of Directors
|
|
Majority of Votes Cast
|
|
2.
|
Ratification of Independent Registered Public Accounting Firm
|
|
Majority of Votes Cast
|
|
3.
|
Say on Pay
|
|
Majority of Votes Cast
|
Q:
|
What if I am a beneficial owner and I do not give the nominee voting instructions?
|
A:
|
If you are a beneficial owner and your shares are held in “street name,” the Broker is bound by the rules of the New York Stock Exchange (“NYSE”) regarding whether or not it can exercise discretionary voting power for any particular proposal if the Broker has not received voting instructions from you. Brokers have the authority to vote shares for which their customers do not provide voting instructions on certain routine matters. A broker non-vote occurs when a Broker returns a proxy but does not vote on a particular proposal because the Broker does not have discretionary authority to vote on the proposal and has not received specific voting instructions for the proposal from the beneficial owner of the shares. Broker non-votes are considered to be present at the meeting for purposes of determining the presence of a quorum but are not counted as votes cast.
|
Proposal
|
|
Can Brokers
Vote Absent
Instructions?
|
|
Impact of
Broker
Non-Vote
|
|
|
|
|
|
|
|
1.
|
Election of Directors
|
|
No
|
|
None
|
2.
|
Ratification of Independent Registered Public Accounting Firm
|
|
Yes
|
|
Not Applicable
|
3.
|
Say on Pay
|
|
No
|
|
None
|
Q:
|
What if I sign and return my proxy without making any selections?
|
A:
|
If you sign and return your proxy without making any selections, your shares will be voted “FOR” each of the director nominees, and “FOR” each of the two other proposals. If other matters properly come before the meeting, the proxy holders will have the authority to vote on those matters for you at their discretion. If your shares are held in “street name,” see the question above on how to vote your shares.
|
Q:
|
How do I change my vote?
|
A:
|
A shareholder of record may revoke his or her proxy by giving written notice of revocation to our Corporate Secretary before the meeting, by delivering a later-dated proxy (either in writing, by telephone or over the Internet), or by voting in person at the 2016 Annual Meeting.
|
Q:
|
What shares are covered by my proxy card?
|
A:
|
Your proxy reflects all shares owned by you at the close of business on March 8, 2016. For participants in our 401(k) plans, shares held in your account as of that date are included in your proxy.
|
Q:
|
What does it mean if I receive more than one proxy card?
|
A:
|
If you receive more than one proxy card, it means that you hold shares in more than one account. To ensure that all of your shares are voted, you should sign and return each proxy card. Alternatively, if you vote by telephone or via the Internet, you will need to vote once for each proxy card and voting instruction card you receive.
|
Q:
|
Who can attend the 2016 Annual Meeting?
|
A:
|
Only shareholders and our invited guests are permitted to attend the 2016 Annual Meeting. To gain admittance, you must bring a form of personal identification to the meeting, where your name will be verified against our shareholder list. If a Broker holds your shares and you plan to attend the meeting, you should bring a brokerage statement showing your ownership of the shares as of the record date or a letter from the Broker confirming such ownership, and a form of personal identification. If you wish to vote your shares that are held by a Broker at the meeting, you must obtain a proxy from your Broker and bring such proxy to the meeting.
|
Q:
|
If I plan to attend the 2016 Annual Meeting, should I still vote by proxy?
|
A:
|
Yes. Casting your vote in advance does not affect your right to attend the 2016 Annual Meeting. If you send in your proxy card and also attend the meeting, you do not need to vote again at the meeting unless you want to change your vote. Written ballots will be available at the 2016 Annual Meeting for shareholders of record.
|
Q:
|
How can I listen to the live audio webcast of the 2016 Annual Meeting?
|
A:
|
You may listen to a live audio webcast of the 2016 Annual Meeting at www.iff.com. The webcast will allow you to listen to the Annual Meeting, but shareholders accessing the 2016 Annual Meeting through the webcast will not be considered present at the 2016 Annual Meeting and will not be able to vote their shares through the webcast or ask questions. If you plan to listen to the live audio webcast, then please submit your vote prior to the 2016 Annual Meeting using one of the methods described under “How do I vote?” above. An archived copy of the webcast will be available at www.iff.com following the 2016 Annual Meeting. Registration to listen to the webcast will be required. We have included our website address for reference only. The information contained on our website is not incorporated by reference into this Proxy Statement.
|
MARCELLO V. BOTTOLI, 54
|
|
![]()
Director Since:
2007
Board Committees:
Compensation (until May 2016)
Audit (beginning May 2016)
|
An Italian national with extensive international experience, Mr. Bottoli has been an operating partner of Advent International, a global private equity firm, since 2010, and served as Interim Chief Executive Officer of Pandora A/S, a designer, manufacturer and marketer of hand-finished and modern jewelry, from August 2011 until March 2012. Mr. Bottoli served as President and Chief Executive Officer of Samsonite Inc., a luggage manufacturer and distributor, from March 2004 through January 2009, and President and Chief Executive Officer of Louis Vuitton Malletier, a manufacturer and retailer of luxury handbags and accessories, from 2001 through 2002. Previously, Mr. Bottoli held a number of roles with Benckiser N.V., and then Reckitt Benckiser plc, a home, health and personal care products company, following the merger of Benckiser with Reckitt & Colman Ltd. His experience as a chief executive and emphasis on consumer products, strategic insights and marketing as well as his experience with strategic transactions, has enabled Mr. Bottoli to provide many insights and contributions to our Board. Mr. Bottoli is Chairman of Pharmafortune S.A., a pharmaceuticals and biotechnology manufacturer, and is a member of the advisory board of Aldo Group, a Canadian footwear retailer, and serves on the board of directors of Desigual, an international fashion retailer based in Spain. Mr. Bottoli served on the board of True Religion Apparel, Inc., a California-based fashion jeans, sportswear and accessory manufacturer and retailer, from 2009 to 2013, on the board of Pandora A/S from 2010 to 2014, on the Board of Ratti Spa, an Italian manufacturer of high-end fabrics and textiles for the fashion industry from 2003 to 2010, and on the Board of Blushington LLC, a California-based makeup and beauty services retailer between 2011 and 2014.
|
|
|
|
|
|
DR. LINDA BUCK, 69
|
|
![]()
Director Since
: 2007
Board Committees:
Nominating and Governance
|
Dr. Linda Buck has been a Howard Hughes Medical Institute Investigator since 1994, a Member of the Fred Hutchinson Cancer Research Center since 2002, and Affiliate Professor of Physiology and Biophysics at the University of Washington since 2003. She was previously Full Professor of Neurobiology at Harvard Medical School. Dr. Buck serves on the Scientific Advisory Boards of The Picower Institute for Learning and Memory at Massachusetts Institute of Technology and The Center for Molecular Medicine, Karolinska Institute, Sweden, and previously served on the Medical Advisory Board of The Gairdner Foundation, a Canadian non-profit organization devoted to the recognition of outstanding achievement in biomedical research worldwide. She is a member of the International Advisory Panel of the Knut and Alice Wallenberg Foundation, the largest private foundation promoting scientific research in Sweden, and the President’s Council of the New York Academy of Sciences. Dr. Buck is an elected Member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts & Sciences, the European Academy of Sciences, and the Royal Society, the United Kingdom’s national academy of science. Dr. Buck’s research has provided key insights into the mechanisms that underlie the sense of smell and she has been the recipient of numerous awards, including The Nobel Prize in Physiology or Medicine in 2004. In May 2015, Dr. Buck received an honorary Doctor of Science degree from Harvard University. Her knowledge is important to our research and development efforts in both flavors and fragrances, as is Dr. Buck’s technical and advisory board experience in evaluating a host of issues. Dr. Buck served on the Board of Directors of DeCode Genetics Inc., a biotechnology company, from 2005 to 2009.
|
|
MICHAEL L. DUCKER, 62
|
|
![]()
Director Since:
2014
Board Committees:
Compensation
|
Mr. Ducker has been President and Chief Executive Officer of FedEx Freight since January 2015. In that role, he provides strategic direction for FedEx's less-than-truckload (LTL) companies throughout North America and for FedEx Custom Critical, a leading carrier of time sensitive, critical shipments. Mr. Ducker was formerly the Chief Operating Officer and President of International for FedEx Express, where he led all customer-facing aspects of the company’s U.S. operations and its international business, spanning more than 220 countries and territories across the globe. Mr. Ducker also oversaw FedEx Trade Networks and FedEx Supply Chain. During his FedEx career, which began in 1975, Mr. Ducker has also served as president of FedEx Express Asia Pacific in Hong Kong and led the Southeast Asia and Middle East regions from Singapore, as well as Southern Europe from Milan, Italy. His significant experience at a global organization complements the strength of our Board. Mr. Ducker serves as an Executive Board Member and Chairman of the U.S. Chamber of Commerce, and as a board member of the Coalition of Service Industries. Mr. Ducker also serves on the board of directors of Amway Corporation, the National Advisory Board of the Salvation Army, the Executive Committee of the American Trucking Association and as a member of the American Transportation Research Institute Board of Directors.
|
|
|
|
|
|
DAVID R. EPSTEIN, 54
|
|
![]()
Director Since:
2016
Board Committees:
Audit
|
Mr. Epstein is Division Head and CEO at Novartis Pharmaceuticals, a division of Novartis AG, a Swiss multinational pharmaceutical company and is a member of Novartis’s Executive Committee. He has been the Head of Novartis Pharmaceuticals since 2010. From September 2000 to February 2010, Mr. Epstein served as President and Chief Executive Officer of Novartis Oncology division. He joined Sandoz, the predecessor of Novartis, in 1989 and held various leadership positions of increasing responsibility, including Chief Operating Officer of Novartis Pharmaceuticals Corporation in the United States and Global Head of Novartis Specialty Medicines until August 2000. Before joining Sandoz, Mr. Epstein was an associate in the strategy practice of Booz Allen Hamilton, a consulting firm. Mr. Epstein’s extensive global business experience and understanding of research and development initiatives provides valuable insights to our Board. Mr. Epstein served on the board of Molecular Insight Pharmaceuticals from 2008 to 2010 and on the board of Novartis Oncology and Molecular Diagnostics from 1999 to 2010. He also participated in the inaugural CEO Roundtable on Cancer, a non-profit organization working to make continual progress toward the elimination of cancer, which was held May 8, 2001 and was the Novartis member representative through 2008.
|
|
ROGER W. FERGUSON, JR., 64
|
|
![]()
Director Since:
2010
Board Committees:
Compensation (Chair)
|
Mr. Ferguson has been the President and Chief Executive Officer of TIAA (formerly TIAA-CREF), a major financial services company, since April 2008. He joined TIAA after his tenure at Swiss Re, a global reinsurance company, where he served as Chairman of the firm’s America Holding Corporation, Head of Financial Services, and a member of the Executive Committee from 2006 to 2008. Mr. Ferguson currently serves on the board of directors of General Mills, Inc., a manufacturer and marketer of branded consumer foods, and the Advisory Board of Brevan Howard Asset Management LLP, a global alternative asset manager. He serves on the boards of a number of charitable and non-governmental organizations, including the Institute for Advanced Study, Memorial Sloan-Kettering Cancer Center, the American Council of Life Insurers, the Partnership for New York, and Math for America. He is Chairman of The Conference Board, a member of the Executive Committee of the Business-Higher Education Forum, and a member of the Economic Club of New York, the Council on Foreign Relations and the Group of Thirty. Mr. Ferguson is also a fellow of the American Academy of Arts and Sciences and co-chair of the Academy’s Commission on the Future of Undergraduate Education. Mr. Ferguson previously served on the Congressional Budget Office's Panel of Economic Advisers. Mr. Ferguson holds a B.A. and a Ph.D. in Economics and a J.D., all from Harvard University. Mr. Ferguson brings to our Board his sound business judgment and extensive knowledge of the finance industry.
|
|
|
|
|
|
JOHN F. FERRARO, 60
|
|
![]()
Director Since:
2015
Board Committees:
Audit (Chair beginning May 2016)
|
Mr. Ferraro was the global chief operating officer of Ernst & Young, a leading professional services firm, from 2007 to January 2015. In that role, he was responsible for the overall operations and services of Ernst & Young worldwide. Prior to the COO role, Mr. Ferraro served in several leadership positions, including as Global Vice Chair of Audit and as the senior advisory partner on some of the firm’s largest and global accounts. Mr. Ferraro began his career with Ernst & Young Milwaukee in 1976 and has served a variety of global companies. He has worked in Europe (London and Rome), throughout the Midwest (Chicago, Cleveland and Kansas City) and New York. Mr. Ferraro has served on the board of Advance Auto Parts, an automotive aftermarket parts provider, since February 2015, and on the board of ManpowerGroup Inc., a global workforce solution and service provider, since January 2016. He founded the Audit Committee Leadership Network in 2003 and is a member of the Boston College High School board of trustees. He is a CPA and a member of the American Institute of Certified Public Accountants. Mr. Ferraro was elected to the Marquette University Board of Trustees in 2006, served as vice chair from 2011 to 2014, and was elected chair in 2014. Mr. Ferraro brings to our Board his extensive accounting, auditing and executive experience working with large and global corporations.
|
|
ANDREAS FIBIG, 54
|
|
![]()
Director Since:
2011
Chairman of the Boar
d
|
Mr. Fibig joined our Board in 2011 and has been our Chairman since December 2014 and Chief Executive Officer since September 2014. Previously, he served as President and Chairman of the Board of Management of Bayer HealthCare Pharmaceuticals, the pharmaceutical division of Bayer AG, from September 2008 to September 2014. Prior to that position, Mr. Fibig held a number of positions of increasing responsibility at Pfizer Inc., a research-based pharmaceutical company, including as Senior Vice President of the US Pharmaceutical Operations group from 2007 through 2008 and as President, Latin America, Africa and Middle East from 2006 through 2007. Mr. Fibig’s prior work experience with various pharmaceutical companies has provided him with extensive experience in international business, product development and strategic planning, which are directly translatable to his work as our Chairman and CEO. Mr. Fibig chairs the Board of Trustees of the Max Planck Institute for Infection Biology.
|
|
|
|
|
|
CHRISTINA GOLD, 68
|
|
![]()
Director Since:
2013
Board Committees:
Compensation, Nominating and Governance
|
From September 2006 until September 2010, Ms. Gold was Chief Executive Officer, President and a director of The Western Union Company, a leader in global money movement and payment services. She was President of Western Union Financial Services, Inc. and Senior Executive Vice President of First Data Corporation, former parent company of The Western Union Company and provider of electronic commerce and payment solutions, from May 2002 to September 2006. Prior to that, Ms. Gold served as Vice Chairman and Chief Executive Officer of Excel Communications, Inc., a former telecommunications and e-commerce services provider, from October 1999 to May 2002. From 1998 to 1999, Ms. Gold served as President and CEO of Beaconsfield Group, Inc., a direct selling advisory firm that she founded. Prior to founding Beaconsfield Group, Ms. Gold spent 28 years (from 1970 to 1998) with Avon Products, Inc., a leading global beauty company, in a variety of positions, including as Executive Vice President, Global Direct Selling Development, Senior Vice President and later President of Avon North America, and Senior Vice President & CEO of Avon Canada. Ms. Gold brings a number of valuable characteristics to our Board, including her extensive international and domestic business experience, her familiarity with the Company’s customer base, her financial expertise and her prior experience as a chief executive officer. Ms. Gold is currently a director of ITT Corporation, a manufacturer of highly engineered components and technology solutions for industrial markets (since 1997), New York Life Insurance, a private mutual life insurance company, and Korn/Ferry International, a leadership and talent management organization. From October 2011 to May 2013, Ms. Gold was a director of Exelis, Inc., a diversified, global aerospace, defense and information solutions company. She also sits on the board of Safe Water Network, a non-profit organization working to develop locally owned, sustainable solutions to provide safe drinking water, and is a member of the Board of Governors of Carleton University in Ottawa, Canada.
|
|
HENRY W. HOWELL, JR., 74
|
|
![]()
Director Since:
2004
Board Committees:
Audit, Nominating and Governance (Chair
)
|
Until 2000, Mr. Howell served in various positions during his 34 years with J.P. Morgan, a financial services firm. At J.P. Morgan, Mr. Howell secured extensive business development, finance and international management experience which enables him to provide both a public and a private sector perspective on corporate finance, corporate governance and mergers and acquisitions. This experience also serves us well in conjunction with his service on our Nominating and Governance and Audit Committees. While at J.P. Morgan, Mr. Howell held several overseas positions including head of banking operations in Germany and Chief Executive Officer of J.P. Morgan’s Australian merchant banking affiliate, which was publicly listed. Both of these assignments enhanced his ability to analyze complex international business and financial matters. He is currently Chairman of the board of trustees of the Norton Art Museum and is a life trustee of the Chicago History Museum.
|
|
|
|
|
|
KATHERINE M. HUDSON, 69
|
|
![]()
Director Since:
2008
Board Committees:
Audit (Chair)(until May 2016)
Compensation (beginning May 2016) |
As Chairperson, President and Chief Executive Officer of Brady Corporation, a global manufacturer of identification solutions and specialty industrial products, from 1994 until 2004, Ms. Hudson oversaw a doubling of annual revenues. Her prior experience during 24 years with Eastman Kodak, an imaging technology products provider, covered various areas of responsibility, including systems analysis, supply chain, finance and information technology. Her general management experience spans both commercial and consumer product lines. Ms. Hudson served as a director of Apple Computer Corporation, a designer and manufacturer of consumer electronics and software products, CNH Global NV, a manufacturer of agricultural and construction equipment where she was as a member of the audit committee, and, between 2000 and 2012, Charming Shoppes, Inc., a woman’s specialty retailer, where she served as chair of the audit committee. Ms. Hudson’s executive experience and her governance leadership on other boards have translated to sound guidance to our Board and as Chair of our Audit Committee.
|
|
|
|
|
|
DALE F. MORRISON, 67
|
|
![]()
Director Since:
2011
Board Committees:
Audit, Nominating and Governance,
Lead Director
(Compensation beginning May 2016)
|
Mr. Morrison has been a founding partner of TriPointe Capital Partners, a private equity firm, since 2011. Prior to TriPointe, he served from 2004 until 2011 as the President and Chief Executive Officer of McCain Foods Limited, an international leader in the frozen food industry. A food industry veteran, his experience includes service as Chief Executive Officer and President of Campbell Soup Company, various roles at General Foods and PepsiCo and as an operating partner of Fenway Partners, a private equity firm. Mr. Morrison is a seasoned executive with strong consumer marketing and international credentials and his knowledge of our customer base is very valuable to our Board. Mr. Morrison is currently Non-Executive Chairman of the Center of Innovation at the University of North Dakota, the Non-Executive Chairman of Findus Group, a frozen foods company, and a director of Hale and Hearty, a restaurant business, and InterContinental Hotels Group, an international hotel company, and he previously served as a director of Trane, Inc.
|
|
•
|
director independence;
|
•
|
director qualifications and responsibilities;
|
•
|
board structure and meetings;
|
•
|
management succession; and
|
•
|
the Chief Executive Officer (“CEO”) evaluation process.
|
•
|
presiding at all meetings of the Board at which the Chairman and CEO is not present, including executive sessions of the independent directors, and providing prompt feedback regarding those meetings to the Chairman and CEO;
|
•
|
approving, and providing suggestions for, Board meeting agendas, with the involvement of the Chairman and CEO and input from other directors;
|
•
|
serving as the liaison between the Chairman and CEO and the independent directors;
|
•
|
monitoring significant issues occurring between Board meetings and assuring Board involvement when appropriate; and
|
•
|
ensuring, in consultation with the Chairman and CEO, the adequate and timely exchange of information between our management and the Board.
|
Name
|
Audit
|
Compensation
|
Nominating and
Governance
|
Lead Director
|
Marcello V. Bottoli
|
X
1
|
X
1
|
|
|
Dr. Linda Buck
|
|
|
X
|
|
Michael L. Ducker
|
|
X
|
|
|
David R. Epstein
|
X
|
|
|
|
Roger W. Ferguson, Jr.
|
|
X (Chair)
|
|
|
John F. Ferraro
|
X (Chair elect)
1
|
|
|
|
Christina Gold
|
|
X
|
X
|
|
Henry W. Howell, Jr.
|
X
|
|
X (Chair)
|
|
Katherine M. Hudson
|
X (Chair)
1
|
X
1
|
|
|
Dale F. Morrison
|
X
|
X
1
|
X
|
X
|
•
|
the financial reporting process and the integrity of our financial statements, capital structure and related financial information;
|
•
|
our internal control environment, systems and performance;
|
•
|
the audit process followed by our independent accountant and our internal auditors;
|
•
|
the appointment, compensation, retention and oversight of our independent accountant and our internal auditors;
|
•
|
our independent accountant's qualifications, performance and independence, and whether it should be rotated, considering the advisability and potential impact of selecting a different independent public accountant; and
|
•
|
the procedures for monitoring compliance with laws and regulations and with our Code of Business Conduct and Ethics.
|
•
|
meets the independence requirements of the NYSE’s corporate governance listing standards;
|
•
|
meets the enhanced independence standards for audit committee members required by the SEC;
|
•
|
is financially literate, knowledgeable and qualified to review financial statements; and
|
•
|
qualifies as an “audit committee financial expert” under SEC rules.
|
•
|
determining, subject to approval by the independent directors of the Board, the CEO’s compensation;
|
•
|
reviewing and making determinations regarding compensation of executive officers (other than the CEO) and other members of senior management;
|
•
|
reviewing, adopting and recommending to the Board, or shareholders as required, general compensation and benefits policies, plans and programs, and overseeing the administration of such policies, plans and programs;
|
•
|
reviewing and discussing with management each year the Compensation Discussion and Analysis included in our annual proxy statement or annual report on Form 10-K;
|
•
|
recommending to the Board any changes to the compensation and benefits of non-employee directors; and
|
•
|
conducting a risk assessment of our overall compensation policies and practices.
|
•
|
meets the independence requirements of the NYSE’s corporate governance listing standards;
|
•
|
is an “outside director” pursuant to the criteria established by the Internal Revenue Service; and
|
•
|
is a “non-employee” director within the meaning of Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
|
•
|
developing and reviewing criteria for the selection of directors, and making recommendations to the Board with respect thereto;
|
•
|
reviewing the suitability of directors for continued service, including in case of a resignation tendered by a director, and making recommendations to the Board with respect to their re-nomination or action to be taken with respect to the resignation;
|
•
|
identifying qualified individuals to serve on the Board, reviewing the qualifications of director candidates and recommending to the Board the nominees to be proposed by the Board for election as directors at the annual meeting of shareholders;
|
•
|
reviewing director candidates recommended by shareholders for election;
|
•
|
establishing and reviewing policies pertaining to roles, responsibilities, tenure and removal of directors;
|
•
|
overseeing CEO and senior management succession plans;
|
•
|
developing and reviewing the Board and Board committee evaluation process and overseeing the annual CEO evaluation process;
|
•
|
reviewing and recommending changes to our Corporate Governance Guidelines and monitoring corporate governance issues; and
|
•
|
reviewing and, if appropriate, approving transactions with related parties.
|
•
|
of at least 3% of the Company’s outstanding shares, which can comprise up to 20 shareholders,
|
•
|
holding the shares continuously for at least 3 years,
|
•
|
can nominate individuals constituting up to 20% of the Board for election at an annual shareholders meeting.
|
•
|
judgment, character, expertise, skills and knowledge useful to the oversight of our business;
|
•
|
diversity of viewpoints, backgrounds, experiences and other demographics;
|
•
|
business or other relevant experience; and
|
•
|
the extent to which the interplay of the candidate’s expertise, skills, knowledge and experience with that of other Board members will build a Board that is effective, collegial and responsive to our needs and to the requirements and standards of the NYSE and the SEC.
|
•
|
the related person’s relationship to the Company and interest in the transaction;
|
•
|
the material facts of the transaction;
|
•
|
the benefits to the Company;
|
•
|
the availability of alternate sources of comparable products or services and the terms of such alternative; and
|
•
|
an assessment as to whether the transaction is on terms comparable to the terms available to an unrelated third party or to employees generally.
|
Name (1)
|
|
Fees Earned or
Paid in Cash($)(2)
|
|
Stock
Awards
($)(3)(4)(5)
|
|
All Other
Compensation
($)(6)
|
|
Total ($)
|
|
Marcello V. Bottoli
|
|
112,569
|
|
107,081
|
|
5,000
|
|
224,650
|
|
Dr. Linda Buck
|
|
112,500
|
|
107,081
|
|
—
|
|
219,581
|
|
J. Michael Cook (7)
|
|
—
|
|
—
|
|
10,000
|
|
10,000
|
|
Michael L. Ducker
|
|
112,500
|
|
107,081
|
|
10,000
|
|
229,581
|
|
Roger W. Ferguson, Jr.
|
|
127,500
|
|
107,081
|
|
—
|
|
234,581
|
|
John F. Ferraro
|
|
112,500
|
|
107,081
|
|
10,000
|
|
229,581
|
|
Christina Gold
|
|
112,569
|
|
107,081
|
|
10,000
|
|
229,650
|
|
Alexandra A. Herzan (7)
|
|
—
|
|
—
|
|
10,000
|
|
10,000
|
|
Henry W. Howell, Jr.
|
|
122,500
|
|
107,081
|
|
10,000
|
|
239,581
|
|
Katherine M. Hudson
|
|
127,500
|
|
107,081
|
|
10,000
|
|
244,581
|
|
Arthur C. Martinez (7)
|
|
—
|
|
—
|
|
10,000
|
|
10,000
|
|
Dale F. Morrison
|
|
132,500
|
|
107,081
|
|
10,000
|
|
249,581
|
|
(1)
|
Mr. Epstein joined our Board in 2016 and is not included in the table above, as he received no director compensation for 2015.
|
(2)
|
The amounts in this column include (i) the annual cash retainer for service as a non-employee director, (ii) for certain directors, the annual cash retainer for service as Lead Director or as chairperson of a Board committee during 2015, and (iii) nominal amounts of cash paid in lieu of fractional shares of common stock. Of the amounts in this column, the following amounts were deferred in 2015 under our DCP: Dr. Buck - $112,500; Mr. Ducker - $112,500; Mr. Ferguson - $127,500; Mr. Ferraro - $112,500; Mr. Howell - $122,500; Ms. Hudson - $127,500; and Mr. Morrison - $132,500. Earnings in our DCP were not above-market or preferential and thus are not reported in this table.
|
(3)
|
The amounts in this column represent the aggregate grant date fair value of equity awards granted during the fiscal year ended December 31, 2015, computed in accordance with FASB ASC Topic 718. Details on and assumptions used in calculating the grant date fair value of RSUs and options may be found in Note 12 to our audited financial statements for the year ended December 31, 2015 included in our Annual Report on Form 10-K filed with the SEC on March 1, 2016.
|
(4)
|
Each director received a grant on May 6, 2015 of 952 RSUs under our 2015 SAIP, other than Messrs. Cook and Martinez and Ms. Herzan, who retired prior to last year's annual meeting. None of our directors forfeited any RSUs or shares of deferred stock during 2015.
|
(5)
|
As of December 31, 2015, the following directors held the following number of unvested RSUs and shares of deferred common stock.
|
Director
|
|
RSUs
|
|
Deferred
Stock
|
|
||
Marcello V. Bottoli
|
|
2,247
|
|
|
12,959
|
|
|
Dr. Linda Buck
|
|
2,247
|
|
|
14,115
|
|
|
Michael L. Ducker
|
|
952
|
|
|
2,213
|
|
|
Roger L. Ferguson, Jr.
|
|
2,247
|
|
|
6,532
|
|
|
John Ferraro
|
|
952
|
|
|
—
|
|
|
Christina Gold
|
|
2,247
|
|
|
—
|
|
|
Henry W. Howell, Jr.
|
|
2,247
|
|
|
39,881
|
|
|
Katherine M. Hudson
|
|
2,247
|
|
|
14,743
|
|
|
Dale F. Morrison
|
|
2,247
|
|
|
9,097
|
|
|
(6)
|
The amounts in this column are contributions made by us under our Matching Gift Program to eligible charitable organizations matching contributions of the director to those charitable organizations during 2015.
|
(7)
|
Each of Messrs. Cook and Martinez and Ms. Herzan retired from our Board in 2015 and therefore did not receive any cash retainer or equity compensation in 2015.
|
Name and Address of Beneficial Owner (1)
|
|
Shares of
Common Stock
Beneficially
Owned(2)(3)
|
|
Percent of
Class**
|
|
|
|
|
|
|
|
Marcello V. Bottoli
|
|
17,451
|
|
(4)
|
*
|
Dr. Linda Buck
|
|
16,362
|
|
(5)
|
*
|
Anne Chwat
|
|
58,871
|
|
(6)
|
*
|
Alison A. Cornell
|
|
3,103
|
|
(7)
|
*
|
Michael L. Ducker
|
|
3,165
|
|
(8)
|
*
|
David R. Epstein
|
|
—
|
|
|
*
|
Roger W. Ferguson, Jr.
|
|
8,779
|
|
(9)
|
*
|
John F. Ferraro
|
|
952
|
|
(10)
|
*
|
Andreas Fibig
|
|
35,760
|
|
(11)
|
*
|
Christina Gold
|
|
3,392
|
|
(12)
|
*
|
Matthias Haeni
|
|
23,678
|
|
(13)
|
*
|
Henry W. Howell, Jr.
|
|
42,128
|
|
(14)
|
*
|
Katherine M. Hudson
|
|
19,490
|
|
(15)
|
*
|
Nicolas Mirzayantz
|
|
78,144
|
|
(16)
|
*
|
Dale F. Morrison
|
|
11,344
|
|
(17)
|
*
|
Richard O’ Leary
|
|
19,900
|
|
(18)
|
*
|
All Directors and Executive Officers as a Group (19 persons)
|
|
437,563
|
|
(19)
|
*
|
*
|
Less than 1%.
|
**
|
Based on 79,685,747 shares of common stock outstanding as of March 8, 2016.
|
(1)
|
Except as otherwise indicated, the address of each person named in the table is c/o International Flavors & Fragrances Inc., 521 West 57th Street, New York, New York 10019.
|
(2)
|
This column includes (i) shares held by our executive officers in our 401(k) Retirement Investment Fund Plan and (ii) shares of Purchased Restricted Stock (“PRS”) held by our executive officers. Shares of PRS are subject to vesting and may be forfeited if the executive’s employment is terminated.
|
(3)
|
In determining the number and percentage of shares beneficially owned by each person, shares that may be acquired by such person within 60 days after March 8, 2016 are deemed outstanding for purposes of determining the total number of outstanding shares for such person and are not deemed outstanding for such purpose for all other shareholders. Certain stock equivalent units held in the IFF Stock Fund under our DCP are premium stock equivalent units paid to executives that are subject to vesting and may be forfeited if the executive’s employment is terminated. To our knowledge, except as otherwise indicated, beneficial ownership includes sole voting and dispositive power with respect to all shares.
|
(4)
|
Includes (i) 2,245 shares held indirectly by a trust for which Mr. Bottoli is the settlor/grantor and Mr. Bottoli and two immediate family members are the beneficiaries, (ii) 12,959 stock equivalent units held in the IFF Stock Fund under our DCP and (iii) 2,247 shares issuable pursuant to RSUs that vest within 60 days after March 8, 2016 that will be automatically deferred to our DCP.
|
(5)
|
Represents (i) 14,115 stock equivalent units held in the IFF Stock Fund under our DCP and (ii) 2,247 shares issuable pursuant to RSUs that vest within 60 days after March 8, 2016 that will be automatically deferred to our DCP.
|
(6)
|
Includes (i) 7,549 stock equivalent units held in the IFF Stock Fund under our DCP and (ii) 3,006 shares earned under the completed 2013-2015 LTIP cycle that have not yet been issued.
|
(7)
|
Includes 495 shares earned under the completed 2013-2015 LTIP cycle that have not yet been issued.
|
(8)
|
Represents (i) 2,213 stock equivalent units held in the IFF Stock Fund under our DCP and (ii) 952 shares pursuant to RSUs that will vest within 60 days after March 8, 2016 that will be automatically deferred to our DCP.
|
(9)
|
Represents (i) 6,532 stock equivalent units held in the IFF Stock Fund under our DCP and (ii) 2,247 shares issuable pursuant to RSUs that vest within 60 days after March 8, 2016 that will be automatically deferred to our DCP.
|
(10)
|
Represents 952 shares issuable pursuant to RSUs that will vest within 60 days after March 8, 2016 that will be automatically deferred to our DCP.
|
(11)
|
Includes (i) 4,602 stock equivalent units held in the IFF Stock Fund under our DCP, (ii) 1,295 shares issuable pursuant to RSUs that vest within 60 days after March 8, 2016 and (iii) 6,114 shares earned under the completed 2013-2015 LTIP cycle that have not yet been issued.
|
(12)
|
Includes 2,247 shares issuable pursuant to RSUs that will vest within 60 days after March 8, 2016, of which 952 shares will be automatically deferred to our DCP.
|
(13)
|
Includes (i) 1,922 shares issuable pursuant to RSUs that will vest within 60 days after March 8, 2016 and (ii) 1,822 shares earned under the completed 2013-2015 LTIP cycle that have not yet been issued.
|
(14)
|
Represents (i) 39,881 stock equivalent units held in the IFF Stock Fund under our DCP and (ii) 2,247 shares issuable pursuant to RSUs that vest within 60 days after March 8, 2016 that will be automatically deferred to our DCP.
|
(15)
|
Includes (i) 14,743 stock equivalent units held in the IFF Stock Fund under our DCP and (ii) 2,247 shares issuable pursuant to RSUs that vest within 60 days after March 8, 2016 that will be automatically deferred to our DCP.
|
(16)
|
Includes (i) 1,543 stock equivalent units held in the IFF Stock Fund under our DCP and (ii) 4,851 shares earned under the completed 2013-2015 LTIP cycle that have not yet been issued.
|
(17)
|
Represents (i) 9,097 stock equivalent units held in the IFF Stock Fund under our DCP and (ii) 2,247 shares issuable pursuant to RSUs that vest within 60 days after March 8, 2016 that will be automatically deferred to our DCP.
|
(18)
|
Includes (i) 1,144 stock equivalent units held in the IFF Stock Fund under our DCP and (ii) 1,570 shares earned under the completed 2013-2015 LTIP cycle that have not yet been issued.
|
(19)
|
Includes an aggregate of (i) 114,621 stock equivalent units held in the IFF Stock Fund under our DCP, (ii) 21,821 shares issuable pursuant to restricted stock units that vest within 60 days after March 8, 2016, and (iii) 24,197 shares earned under the completed 2013-2015 LTIP cycle that have not yet been issued.
|
Name and Address of Beneficial Owner
|
|
Number of Shares and
Nature of Beneficial Ownership
|
|
Percent
of Class*
|
||
|
|
|
|
|
||
BlackRock, Inc.
55 East 52nd Street
New York, NY 10055
|
|
4,655,216
|
|
(1)
|
5.8
|
%
|
Capital Research Global Investors
333 South Hope Street
Los Angeles, CA 90071
|
|
6,225,302
|
|
(2)
|
7.8
|
%
|
The Vanguard Group
100 Vanguard Blvd.
Malvern, PA 19355
|
|
7,467,990
|
|
(3)
|
9.4
|
%
|
*
|
Based on 79,685,747 shares of common stock outstanding.
|
(1)
|
This amount is based solely on Amendment No. 6 to Schedule 13G filed with the SEC on January 26, 2016 by BlackRock, Inc. Of these shares, BlackRock has the sole power to vote or direct the vote with respect to 3,969,533 of these shares and sole power to dispose of or direct the disposition of 4,655,216 of these shares.
|
(2)
|
This amount is based solely on Amendment No. 3 to Schedule 13G filed with the SEC on February 16, 2016 by Capital Research Global Investors, a division of Capital Research and Management Company (“Capital Research”). Capital Research has the sole power to vote or direct the vote and the sole power to dispose of or direct the disposition of these shares.
|
(3)
|
This amount is based solely on Amendment No. 5 to Schedule 13G filed with the SEC on February 10, 2016 by The Vanguard Group. Of these shares, The Vanguard Group has the (i) sole power to vote or direct the vote with respect to 149,808 of these shares, (ii) shared power to vote or direct the vote with respect to 7,700 of these shares, (iii) the sole power to dispose of or direct the disposition of 7,308,518 of these shares, and (iv) shared power to dispose of or direct the disposition of 159,472 of these shares.
|
|
2015
|
|
2014
|
||||
Audit Fees (1)
|
$
|
4,674,019
|
|
|
$
|
4,733,219
|
|
Audit-Related Fees (2)
|
$
|
60,006
|
|
|
$
|
610,004
|
|
Tax Fees (3)
|
|
|
|
||||
Tax Compliance
|
$
|
554,447
|
|
|
$
|
1,148,853
|
|
Other Tax Services
|
$
|
90,786
|
|
|
$
|
82,127
|
|
All Other Fees (4)
|
$
|
67,849
|
|
|
$
|
63,799
|
|
Total
|
$
|
5,447,107
|
|
|
$
|
6,638,002
|
|
(1)
|
Audit Fees were for professional services rendered for audits of our consolidated financial statements and statutory and subsidiary audits, consents and review of reports filed with the SEC and consultations concerning financial accounting and reporting standards. Audit Fees also included the fees associated with an annual audit of our internal control over financial reporting, as required by Section 404 of the Sarbanes- Oxley Act of 2002, integrated with the audit of our annual financial statements.
|
(2)
|
Audit-Related Fees were for due diligence.
|
(3)
|
Tax Compliance services consisted of fees related to the preparation of tax returns, assistance with tax audits and appeals, indirect taxes, expatriate tax compliance services and transfer pricing services. Other Tax Services consisted of tax planning and tax advisory services.
|
(4)
|
All Other Fees were for software licenses and other professional services.
|
•
|
the quality and effectiveness of PwC’s historical and recent performance on the Company’s audit;
|
•
|
the length of PwC’s tenure as the Company’s independent registered public accounting firm, and its familiarity with our business, accounting policies and practices, and internal control over financial reporting;
|
•
|
PwC’s capability, understanding and expertise in handling the breadth and complexity of our global operations;
|
•
|
the appropriateness of PwC’s fees and payment terms; and
|
•
|
PwC’s independence.
|
|
Audit Committee
|
|
|
|
Katherine M. Hudson (Chair)
|
|
|
|
David R. Epstein
John Ferraro
Henry W. Howell, Jr.
Dale F. Morrison
|
|
Andreas Fibig
|
|
Chairman and CEO
|
|
Alison A. Cornell
|
|
CFO
|
|
Nicolas Mirzayantz
|
|
Group President, Fragrances
|
|
Matthias Haeni
|
|
Group President, Flavors
|
|
Anne Chwat
|
|
General Counsel
|
|
Richard O’Leary
|
|
Former Interim CFO
|
(1)
|
Compensation for Mr. O’Leary is not included in the amounts reflected due to his status as interim CFO and the distinct nature of his compensation. Compensation for Ms. Cornell is included on an annualized basis.
|
(1)
|
Compensation for Mr. O’Leary is not included in the amounts reflected due to his status as interim CFO and the distinct nature of his compensation. Compensation for Ms. Cornell is included on an annualized basis.
|
•
|
Our clawback policies for recovery of cash and equity compensation from executives apply to accounting restatements, financial restatements and misstatements (without regard to fault), an employee’s willful misconduct or violation of a Company policy that is materially detrimental to the Company, and an employee’s violation of non-competition, non-solicitation, confidentiality and similar covenants;
|
•
|
We require our executives, including our NEOs, to meet share retention guidelines to align our executives’ interests with those of our shareholders, as described above under “Share Retention Policy”;
|
•
|
We do not permit short-sales or hedging of our stock by our employees, officers or directors;
|
•
|
Our Executive Severance Policy (“ESP”) provides that all equity awards are subject to a “double trigger” and only accelerate in connection with a change in control if an ESP participant is terminated without cause or terminates for “good reason” within two years following a change in control; and
|
•
|
None of our NEOs are entitled to a tax gross-up for severance payments.
|
1.
|
U.S. publicly traded companies of comparable size with manufacturing operations (generally based on revenue of $1B - $7B and market capitalization of $1B - $14B);
|
2.
|
Strong in-house R&D activities;
|
3.
|
Global scope with significant international presence (international operations generally accounting for at least 25% of total revenues);
|
4.
|
Growth orientation, with positive sales and earnings growth over the three years prior to the review and selection of the peer group;
|
5.
|
Companies with which we compete for executive talent; and
|
6.
|
Progressive companies with positive reputations.
|
Church & Dwight Co., Inc.
|
Hormel Foods Corporation
|
The Clorox Company
|
Jarden Corporation
|
Coty, Inc.
|
McCormick & Company, Incorporated
|
Elizabeth Arden, Inc.
|
Newell Rubbermaid Inc.
|
Energizer Holdings, Inc.
|
Nu Skin Enterprises, Inc.
|
The Estee Lauder Companies Inc.
|
Revlon, Inc.
|
Herbalife Ltd.
|
Sensient Technologies Corporation
|
The Hershey Company
|
Tupperware Brands Corporation
|
Acuity Brands
|
|
Jack In The Box Inc.
|
Armstrong World Industries, Inc.
|
|
The J.M. Smucker Company
|
Beam
|
|
Lorillard, Inc.
|
Brown-Forman
|
|
Mattel, Inc.
|
Brunswick
|
|
Molson Coors Brewing Company
|
The Estee Lauder Companies Inc.
|
|
Newell Rubbermaid Inc.
|
Hanesbrands Inc.
|
|
Nu Skin Enterprises
|
Harman International Industries, Incorporated
|
|
Polaris Industries Inc.
|
Hasbro, Inc.
|
|
Revlon, Inc.
|
The Hershey Company
|
|
Steelcase Inc.
|
HNI
|
|
Tupperware Brands Corporation
|
Hormel
|
|
|
•
|
individual experience and performance;
|
•
|
scope of responsibilities;
|
•
|
relative responsibilities compared with other senior Company executives;
|
•
|
contribution relative to overall Company performance;
|
•
|
compensation relative to his or her peers within the organization; and
|
•
|
long-term potential.
|
Element
|
|
Fixed or Variable
|
|
|
Primary Objective
|
Base Salary
|
|
Fixed
|
|
•
|
To attract and retain executives by offering salary that is competitive with market opportunities and that recognizes each executive’s position, role, responsibility and experience.
|
|
|
|
|
|
|
AIP award
|
|
Variable
|
|
•
|
To motivate and reward the achievement of our annual performance objectives, including local currency sales growth, operating profit, gross margin, working capital, and individual objectives.
|
|
|
|
|
|
|
LTIP award
|
|
Variable
|
|
•
|
To motivate and reward the annual profitability performance and the annual and cumulative relative TSR performance over rolling three-year periods.
|
|
•
|
To align executives’ interests with those of shareholders by paying 50% of the earned award in shares of our common stock (with the remaining 50% being payable in cash) and including TSR as a key measure of long-term performance.
|
|||
|
|
|
|
|
|
ECP award
|
|
Variable
|
|
•
|
To align executives’ interests with the interests of shareholders through equity-based compensation.
|
|
•
|
To encourage direct investment in the Company.
|
|||
|
•
|
To serve as an important retention tool.
|
|
2015 Salary
|
|
Target AIP as
% Base Salary
|
|
AIP Target
|
|||||
Andreas Fibig
|
|
$1,200,000
|
|
|
120
|
%
|
|
|
$1,440,000
|
|
Alison A. Cornell(1)
|
|
$560,000
|
|
|
80
|
%
|
|
|
$448,000
|
|
Nicolas Mirzayantz
|
|
$600,000
|
|
|
80
|
%
|
|
|
$480,000
|
|
Matthias Haeni
|
|
$500,000
|
|
|
80
|
%
|
|
|
$400,000
|
|
Anne Chwat
|
|
$465,000
|
|
|
60
|
%
|
|
|
$279,000
|
|
Richard O’Leary(2)
|
|
$445,311
|
|
|
50
|
%
|
|
|
$220,603
|
|
(1)
|
Reflects Ms. Cornell’s salary and AIP target on an annualized basis. Her actual 2015 AIP payout was calculated on a pro rata basis to reflect her appointment as CFO effective as of July 8, 2015.
|
(2)
|
Includes Mr. O’Leary’s salary as interim CFO through Ms. Cornell’s appointment as CFO in July 2015 (including the $7,500 per month that was deferred until appointment of the permanent CFO) and as Controller and Chief Accounting Officer thereafter. Mr. O’Leary’s AIP target percentage remained unchanged following his change in role.
|
Threshold
|
—
|
|
25
|
%
|
Target
|
—
|
|
100
|
%
|
Maximum
|
—
|
|
200
|
%
|
•
|
Local currency sales growth reflects both increases in market share and sales expansion, which drives increases in gross profit. By measuring achievement exclusive of currency fluctuations, this goal helps to ensure that we are rewarding real incremental growth.
|
•
|
An increase in operating profit (in dollar terms) encourages the management of gross profit dollars against operating expenses. Achieving this goal helps provide the Company with the funding to reinvest in the business to drive future growth.
|
•
|
Improvement in gross margin percentage is an important measure for analyzing our ability to effectively recover increases in the cost of raw materials, cost discipline and operating efficiencies.
|
•
|
Reductions in working capital drive better operating cash flow generation. For this purpose, we define working capital as inventories and trade accounts receivable less trade accounts payable.
|
|
|
Corporate Participants(1)
|
|
Business Unit Participants(2)
|
|||||||||||
Performance Metric
|
|
Corporate Weighting
|
|
Bus. Unit Weighting
|
|
Corporate Weighting
|
|
Bus. Unit Weighting
|
|
Total Weighting
|
|||||
Local Currency Sales Growth
|
|
40
|
%
|
|
0
|
%
|
|
20
|
%
|
|
20
|
%
|
|
40
|
%
|
Operating Profit
|
|
25
|
%
|
|
0
|
%
|
|
12.5
|
%
|
|
12.5
|
%
|
|
25
|
%
|
Gross Margin
|
|
15
|
%
|
|
0
|
%
|
|
0
|
%
|
|
15
|
%
|
|
15
|
%
|
Working Capital
|
|
10
|
%
|
|
0
|
%
|
|
10
|
%
|
|
0
|
%
|
|
10
|
%
|
Individual
|
|
10
|
%
|
|
0
|
%
|
|
0
|
%
|
|
0
|
%
|
|
10
|
%
|
Total
|
|
100
|
%
|
|
0
|
%
|
|
42.5
|
%
|
|
47.5
|
%
|
|
100
|
%
|
(1)
|
All NEOs except our two Group Presidents.
|
(2)
|
Our two Group Presidents.
|
Performance Metric
|
|
Threshold
|
|
Target
|
|
Maximum
|
|
Actual
|
|
Award
Payout
(as % of
Target)
|
|
Corporate
Weighting
|
|
Total
Weighted
Award
|
|||||||
Local Currency Sales Growth
|
|
2.3
|
%
|
|
4.8
|
%
|
|
7.3
|
%
|
|
2.7
|
%
|
|
37.0
|
%
|
|
40
|
%
|
|
14.8
|
%
|
Operating Profit
|
|
$611M
|
|
|
$643M
|
|
|
$675M
|
|
|
$603M
|
|
|
—
|
|
|
25
|
%
|
|
—
|
|
Gross Margin
|
|
44.0
|
%
|
|
45.5
|
%
|
|
47.0
|
%
|
|
45.0
|
%
|
|
75.0
|
%
|
|
15
|
%
|
|
11.3
|
%
|
Working Capital
|
|
30.0
|
%
|
|
28.5
|
%
|
|
27.0
|
%
|
|
28.7
|
%
|
|
91.7
|
%
|
|
10
|
%
|
|
9.2
|
%
|
Individual Objectives
|
|
—
|
|
|
—
|
|
|
—
|
|
|
100.0
|
%
|
|
69.0
|
%
|
|
10
|
%
|
|
6.9
|
%
|
Total Award (as % Target)
|
|
25
|
%
|
|
100
|
%
|
|
200
|
%
|
|
|
|
—
|
|
|
100
|
%
|
|
42.2
|
%
|
Performance
Metric
|
|
Threshold
|
|
Target
|
|
Max.
|
|
Award
Payout
(as % of
Target)
|
|
Bus.
Unit
Weight
|
|
Bus. Unit
Weighted
Award
|
|
Corp.
Weight %
|
|
Corp.
Weighted
Award
|
|
Total
Weighted
Award
|
|||||||||
Local Currency Sales Growth
|
|
2.2
|
%
|
|
4.7
|
%
|
|
7.2
|
%
|
|
37.0
|
%
|
|
20
|
%
|
|
7.4
|
%
|
|
20
|
%
|
|
7.4
|
%
|
|
14.8
|
%
|
Operating Profit
|
|
$333M
|
|
|
$349M
|
|
|
$376M
|
|
|
—
|
|
|
12.5
|
%
|
|
—
|
|
|
12.5
|
%
|
|
—
|
|
|
—
|
|
Gross Margin
|
|
44.3
|
%
|
|
45.8
|
%
|
|
47.3
|
%
|
|
50.0
|
%
|
|
15
|
%
|
|
7.5
|
%
|
|
—
|
|
|
—
|
|
|
7.5
|
%
|
Working Capital
|
|
33.2
|
%
|
|
31.5
|
%
|
|
29.8
|
%
|
|
95.5
|
%
|
|
0%
|
|
|
—
|
|
|
10
|
%
|
|
9.2
|
%
|
|
9.2
|
%
|
Individual
|
|
—
|
|
|
—
|
|
|
—
|
|
|
69.0
|
%
|
|
10
|
%
|
|
6.9
|
%
|
|
—
|
|
|
—
|
|
|
6.9
|
%
|
Total Award (as % Target)
|
|
25
|
%
|
|
100
|
%
|
|
200
|
%
|
|
—
|
|
|
57.5
|
%
|
|
—
|
|
|
42.5
|
%
|
|
—
|
|
|
38.4
|
%
|
Performance
Metric
|
|
Threshold
|
|
Target
|
|
Max.
|
|
Award
Payout
(as % of
Target)
|
|
Bus.
Unit
Weight
|
|
Bus. Unit
Weighted
Award
|
|
Corp. Weight %
|
|
Corp
Weighted
Award
|
|
Total
Weighted
Award
|
|||||||||
Local Currency Sales Growth
|
|
2.8
|
%
|
|
5.3
|
%
|
|
7.8
|
%
|
|
37.0
|
%
|
|
20
|
%
|
|
7.4
|
%
|
|
20
|
%
|
|
7.4
|
%
|
|
14.8
|
%
|
Operating Profit
|
|
$326M
|
|
|
$342M
|
|
|
$369M
|
|
|
—
|
|
|
12.5
|
%
|
|
—
|
|
|
12.5
|
%
|
|
—
|
|
|
—
|
|
Gross Margin
|
|
43.0
|
%
|
|
44.5
|
%
|
|
46.0
|
%
|
|
65.0
|
%
|
|
15
|
%
|
|
9.8
|
%
|
|
—
|
|
|
—
|
|
|
9.8
|
%
|
Working Capital
|
|
26.6
|
%
|
|
25.3
|
%
|
|
24.0
|
%
|
|
115.0
|
%
|
|
0%
|
|
|
—
|
|
|
10
|
%
|
|
9.2
|
%
|
|
9.2
|
%
|
Individual
|
|
—
|
|
|
—
|
|
|
—
|
|
|
69.0
|
%
|
|
10
|
%
|
|
6.9
|
%
|
|
—
|
|
|
—
|
|
|
6.9
|
%
|
Total Award (as % Target)
|
|
25
|
%
|
|
100
|
%
|
|
200
|
%
|
|
—
|
|
|
57.5
|
%
|
|
—
|
|
|
42.5
|
%
|
|
—
|
|
|
40.7
|
%
|
|
|
2015
AIP Target ($)
|
|
2015 Payout
|
|||||||
Executive
|
|
As % of Target
|
|
Award ($)
|
|||||||
Andreas Fibig
|
|
|
$1,440,000
|
|
|
42
|
%
|
|
|
$607,680
|
|
Alison Cornell(1)
|
|
|
$448,000
|
|
|
20
|
%
|
|
|
$91,679
|
|
Nicolas Mirzayantz
|
|
|
$480,000
|
|
|
38
|
%
|
|
|
$184,320
|
|
Matthias Haeni
|
|
|
$400,000
|
|
|
41
|
%
|
|
|
$162,800
|
|
Anne Chwat
|
|
|
$279,000
|
|
|
42
|
%
|
|
|
$117,738
|
|
Richard O’Leary(2)
|
|
|
$220,603
|
|
|
42
|
%
|
|
|
$93,094
|
|
(1)
|
Reflects Ms. Cornell’s AIP target on an annualized basis. The actual 2015 AIP payout was calculated on a pro rata basis to reflect her appointment as CFO effective as of July 8, 2015.
|
(2)
|
Mr. O’Leary’s actual 2015 AIP payment was calculated based on his actual salary received in 2015.
|
Segment
|
|
Economic Profit
(EP) Growth
|
|
Total Shareholder
Return (TSR)
relative to the S&P
500
|
|
Total Weighting of
Segment
|
|||
Year 1
|
|
12.5
|
%
|
|
12.5
|
%
|
|
25
|
%
|
Year 2
|
|
12.5
|
%
|
|
12.5
|
%
|
|
25
|
%
|
Year 3
|
|
12.5
|
%
|
|
12.5
|
%
|
|
25
|
%
|
Cumulative Segment (Year 1-Year 3)
|
|
0
|
%
|
|
25
|
%
|
|
25
|
%
|
Total LTIP Cycle
|
|
37.5
|
%
|
|
62.5
|
%
|
|
100
|
%
|
NEO
|
|
Total
LTIP Target Award
|
||
Andreas Fibig
|
|
|
$2,000,000
|
|
Alison A. Cornell (1)
|
|
|
$500,000
|
|
Nicolas Mirzayantz
|
|
|
$500,000
|
|
Matthias Haeni
|
|
|
$500,000
|
|
Anne Chwat
|
|
|
$279,000
|
|
Richard O’Leary
|
|
|
$195,395
|
|
(1)
|
Reflects Ms. Cornell’s LTIP target on an annualized basis. Ms. Cornell’s actual LTIP award was pro-rated to reflect her partial year of employment.
|
Criteria
|
|
Threshold (25%)
|
|
Target (100%)
|
|
Maximum (200%)
|
Cumulative TSR vs. S&P 500
|
|
35th percentile
|
|
55th percentile
|
|
75th percentile
|
Criteria
|
|
Threshold (25%)
|
|
Target (100%)
|
|
Maximum (200%)
|
EP
|
|
$270M
|
|
$294M
|
|
$318M
|
Annual TSR vs S&P 500
|
|
35th percentile
|
|
55th percentile
|
|
75th percentile
|
Segment
|
|
Segment
Weighted
EP Result
|
|
Segment
Weighted
TSR Result
|
|
Combined
Segment
Weighted
Result
|
|
Segment
Weighting
|
|
Overall
Result
|
|||||
2013
|
|
191
|
%
|
|
77
|
%
|
|
133.8
|
%
|
|
25.00
|
%
|
|
33.4
|
%
|
2014
|
|
133
|
%
|
|
112
|
%
|
|
122.4
|
%
|
|
25.00
|
%
|
|
30.6
|
%
|
2015
|
|
34
|
%
|
|
200
|
%
|
|
117.0
|
%
|
|
25.00
|
%
|
|
29.3
|
%
|
Cumulative
|
|
—
|
|
|
196
|
%
|
|
195.5
|
%
|
|
25.00
|
%
|
|
48.9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Total
|
|
|
|
|
|
|
|
100.00
|
%
|
|
142.2
|
%
|
|
|
Lower Limit
|
|
Midpoint
|
|
Upper Limit
|
CEO
|
|
$1,000,000
|
|
$2,000,000
|
|
$3,500,000
|
Group Presidents and CFO
|
|
$250,000
|
|
$500,000
|
|
$750,000
|
General Counsel
|
|
$175,000
|
|
$350,000
|
|
$525,000
|
Types of
Equity
|
|
Description of Equity Type
|
|
Adjustment
Factor
|
PRS
|
|
PRS are shares of restricted stock or restricted stock units, which the Company grants as a match against shares of our stock purchased at full value by an ECP participant on the grant date. As an incentive to promote share accumulation and direct investment in our stock, there is a 20% adjustment upward of the award value if PRS is elected. If an ECP participant chooses PRS, then he or she must deliver funds (or shares with an equivalent value) equal to the dollar amount of the ECP award (including the 20% adjustment) that he or she is electing to receive in PRS. Upon receipt of the funds by the Company, the ECP participant receives a matching number of PRS shares or RSUs from the Company.
During the restricted period, a PRS holder has the same rights as an ordinary shareholder including the right to vote and dividend rights (or dividend equivalents in the case of restricted stock units). Holders of restricted stock units have no voting rights during the vesting period. On the vesting date, which is approximately three years from the date of grant, PRS shares become unrestricted. PRS shares are the most rapid way for participants to accumulate and build share ownership based on the participant’s direct investment in our stock.
|
|
120%
|
SSARs
|
|
SSARs are a contractual right to receive the value, in shares of Company stock, of the appreciation in our stock price from the SSAR grant date to the date the SSAR is exercised by the participant. As an approximation of binomial stock option valuation methods used under ASC Topic 718 (as used for financial reporting purposes), participants receive a number of SSARs equivalent to 4.5 times the elected SSAR award value divided by the grant price. SSARs provide upside potential for share accumulation and alignment with shareholders because SSARS only have value if the stock price increases after the grant date. The adjustment factor for SSARs is 1.0.
SSARs become exercisable on a stated vesting date, which is approximately three years from the grant date, and expire on the seventh anniversary of the grant date. SSARs do not require a financial investment by the SSAR grantee.
|
|
100%
|
RSUs
|
|
RSUs are our promise to issue unrestricted shares of our stock on the stated vesting date, which is approximately three years from the grant date. The adjustment factor for RSUs is 1.0. RSUs do not require a financial investment by the RSU grantee.
|
|
100%
|
Assumes a Common Share Value of $100.00 at Award(1)
|
||||||||||||
|
|
PRS(2)
|
|
RSUs
|
|
SSARs(3)
|
||||||
Award Value
|
|
|
$500,000
|
|
|
|
$500,000
|
|
|
|
$500,000
|
|
Adjustment Factor
|
|
1.2
|
|
|
1.0
|
|
|
1.0
|
|
|||
Post-Factor Value
|
|
|
$600,000
|
|
|
|
$500,000
|
|
|
|
$500,000
|
|
Participant Required Investment
|
|
|
$600,000
|
|
|
—
|
|
|
—
|
|
||
Award Shares/SSARs At Grant Date
|
|
6,000 Shares
|
|
|
5,000 Shares
|
|
|
22,500 SSARs
|
|
|||
Dollar Value of Award At Vesting/Exercise (Assuming 8% Compounded Annual Stock Price Increase) (2)
|
|
|
$755,827
|
|
|
|
$629,856
|
|
|
|
$584,352
|
|
Dollar Value of Award At Vesting/Exercise (Assuming 8% Compounded Annual Stock Price Decrease)
|
|
|
$476,299
|
|
|
|
$396,916
|
|
|
—
|
|
(1)
|
Share values and share value increase/decrease are used in this table are for illustrative purposes only and are not intended as forecasts of future stock price performance.
|
(2)
|
PRS values at grant and vesting include the participant’s appreciation or loss on the required investment in addition to the value of the granted restricted stock. The values exclude dividends.
|
(3)
|
The examples above illustrate value delivered for each ECP grant form over the approximate three-year vesting period. However, SSARs are only taxable when the SSAR is exercised. Participants may choose to hold their SSARs longer than the three-year vesting period (up to the full seven-year contractual term) and continue to participate in future stock price appreciation, if any.
|
|
2015 Unadjusted
ECP Award
|
|
PRS Election
|
|
RSU Election
|
||||||||||||
|
Percent Election
|
|
Adjusted
Value
|
|
Percent Election
|
|
Adjusted
Value
|
||||||||||
Adjustment Factor
|
|
|
|
|
120
|
%
|
|
|
|
100
|
%
|
||||||
Andreas Fibig
|
|
$2,000,000
|
|
|
55
|
%
|
|
|
$1,320,000
|
|
|
45
|
%
|
|
|
$900,000
|
|
Alison A. Cornell (1)
|
|
$250,000
|
|
|
100
|
%
|
|
|
$300,000
|
|
|
—
|
|
|
—
|
|
|
Nicolas Mirzayantz
|
|
$700,000
|
|
|
100
|
%
|
|
|
$840,000
|
|
|
—
|
|
|
—
|
|
|
Matthias Haeni
|
|
$400,000
|
|
|
100
|
%
|
|
|
$480,000
|
|
|
—
|
|
|
—
|
|
|
Anne Chwat
|
|
$500,000
|
|
|
100
|
%
|
|
|
$600,000
|
|
|
—
|
|
|
—
|
|
|
Richard O’Leary
|
|
$250,000
|
|
|
100
|
%
|
|
|
$300,000
|
|
|
—
|
|
|
—
|
|
(1)
|
Represents prorated amount received by Ms. Cornell based on her hire date.
|
•
|
Company car or car allowance;
|
•
|
Annual physical exam;
|
•
|
Financial planning and tax preparation (up to approximately $10,000 per year);
|
•
|
Estate planning (up to $4,000 over a three-year period); and
|
•
|
Health club membership (up to $3,000 annually).
|
|
Compensation Committee
|
|
|
|
Roger W. Ferguson, Jr. (Chair)
|
|
|
|
Marcello V. Bottoli
Michael Ducker
Christina Gold
|
•
|
Our AIP rewards the achievement of our annual performance objectives by providing awards based on the attainment of (1) four financial performance metrics: (i) local currency sales growth, (ii) operating profit, (iii) gross margin and (iv) working capital and (2) individual objectives relating to leadership, succession, planning and people development.
|
•
|
Our LTIP rewards solid Company performance by providing awards based on (i) EP and (ii) TSR performance relative to the S&P 500. In addition, the LTIP aligns our executives’ interests with those of our shareholders by paying 50% of the earned award in shares of our common stock.
|
•
|
Our ECP incentivizes our executives to create value for our shareholders by providing equity-based compensation and encouraging direct investment by our executives.
|
•
|
We require our NEOs to meet certain stock ownership guidelines under our Share Retention Policy to promote alignment of our executives’ interests with those of our shareholders and to discourage excessive risk taking for short-term gains.
|
•
|
our current CEO;
|
•
|
our current CFO and former interim CFO; and
|
•
|
our three other most highly compensated executive officers who were serving as executive officers as of December 31, 2015.
|
Name and
Principal Position
|
|
Year
|
|
Salary
($)(1)
|
|
Bonus
($)
|
|
Stock
Awards
($)(2)(3)
|
|
|
Non-Equity
Incentive Plan
Compensation
($)(4)(5)
|
|
Change in
Pension
Value and
Nonqualified
Deferred
Compensation
Earnings
($)(6)
|
|
All Other
Compensation
($)(7)
|
|
Total
($)
|
|||||||
Andreas Fibig
|
|
2015
|
|
1,200,000
|
|
|
—
|
|
|
3,173,165
|
|
|
|
1,702,478
|
|
|
—
|
|
|
133,099
|
|
|
6,208,742
|
|
Chairman and CEO
|
|
2014
|
|
400,000
|
|
|
1,000,000
|
|
|
2,244,414
|
|
|
|
760,534
|
|
|
—
|
|
|
134,027
|
|
|
4,538,975
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Alison A. Cornell (8)
|
|
2015
|
|
271,562
|
|
|
250,000
|
|
|
506,228
|
|
|
|
217,787
|
|
|
—
|
|
|
32,996
|
|
|
1,278,573
|
|
CFO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Richard O’Leary (9)
|
|
2015
|
|
445,311
|
|
|
—
|
|
|
541,687
|
|
|
|
200,542
|
|
|
—
|
|
|
78,053
|
|
|
1,265,593
|
|
Former Interim CFO
|
|
2014
|
|
302,872
|
|
|
—
|
|
|
349,635
|
|
|
|
225,148
|
|
|
—
|
|
|
86,897
|
|
|
964,552
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Nicolas Mirzayantz
|
|
2015
|
|
585,000
|
|
|
—
|
|
|
1,088,973
|
|
|
|
506,351
|
|
|
—
|
|
|
169,083
|
|
|
2,349,407
|
|
Group President, Fragrances
|
|
2014
|
|
532,500
|
|
|
—
|
|
|
2,998,513
|
|
|
|
762,039
|
|
|
303,665
|
|
|
163,172
|
|
|
4,759,889
|
|
2013
|
|
510,000
|
|
|
—
|
|
|
946,526
|
|
|
|
1,000,974
|
|
|
(96,591
|
)
|
|
122,110
|
|
|
2,483,019
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Matthias Haeni
|
|
2015
|
|
490,000
|
|
|
—
|
|
|
729,004
|
|
|
|
375,043
|
|
|
—
|
|
|
782,736
|
|
|
2,376,783
|
|
Group President, Flavors
|
|
2014
|
|
445,653
|
|
|
—
|
|
|
624,912
|
|
|
|
407,888
|
|
|
—
|
|
|
485,920
|
|
|
1,964,373
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Anne Chwat
|
|
2015
|
|
465,000
|
|
|
—
|
|
|
738,915
|
|
|
|
308,330
|
|
|
—
|
|
|
155,487
|
|
|
1,667,732
|
|
General Counsel
|
|
2014
|
|
465,000
|
|
|
—
|
|
|
708,594
|
|
|
|
419,022
|
|
|
—
|
|
|
562,425
|
|
|
2,155,041
|
|
|
|
2013
|
|
461,250
|
|
|
—
|
|
|
650,471
|
|
|
|
606,067
|
|
|
—
|
|
|
144,650
|
|
|
1,862,438
|
|
(1)
|
The 2015 amounts in this column include (i) the following amounts deferred under the DCP: Ms. Cornell -- $81,667; Mr. Mirzayantz - $58,500; and Ms. Chwat - $139,500, and (ii) the following amounts deferred under the Retirement Investment Fund Plan (401(k)): Mr. Fibig - $24,000; Ms. Cornell - $3,000; Mr. O’Leary - $22,839; Mr. Mirzayantz - $24,000; and Ms. Chwat - $24,000.
|
(2)
|
The amounts in the Stock Awards and Option Awards columns represent the aggregate grant date fair value of equity awards granted during each respective fiscal year, calculated in accordance with FASB ASC Topic 718. Details on and assumptions used in calculating the grant date fair value of RSUs, PRS, SSARs, options and LTIP equity incentive compensation may be found in Note 12 to our audited financial statements for the fiscal year ended December 31, 2015 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. The grant date fair value attributable to the 2015-2017 LTIP cycle awards included in the Stock Awards column pertains to the 50% portion of those awards that will be payable in our common stock if the performance conditions are satisfied and is based on the probable outcome of such conditions. The value of these awards at the grant date if the maximum level of performance conditions were to be achieved is as follows: Mr. Fibig - $2,035,200; Ms. Cornell -- $421,541; Mr. O’Leary - $198,835; Mr. Mirzayantz - $508,800; Mr. Haeni - $508,800; and Ms. Chwat - $283,910. The actual number of shares earned by the NEOs for the completed 2013-2015 LTIP cycle, for the 2015 segment of the 2014-2016 LTIP cycle, and for the 2015 segment of the 2015-2017 LTIP cycle can be found in the narrative following the Grants of Plan-Based Awards Table under the heading “Long-Term Incentive Plan.”
|
(3)
|
The grant date fair value attributable to PRS awards included in the Stock Awards column pertains to the value of the matching portion of the award. Not reflected in this column is the value of shares delivered or cash paid by NEOs to purchase shares in fiscal year 2015 for the participant’s portion of the PRS award. As discussed in the Compensation Discussion and Analysis, participants in our ECP are permitted to satisfy the purchase price of PRS shares by tendering shares of our common stock or paying cash. The following NEOs purchased or tendered the number of shares indicated in fiscal year 2015, in each case at a price per share equal to the closing stock price on the date of grant: Mr. Fibig - $1,319,886 for 11,176 shares; Ms. Cornell - $299,894 for 2,608 shares; Mr. O’Leary - $299,974 for 2,540 shares; Mirzayantz - $839,927 for 7,112 shares; Mr. Haeni - $479,958 for 4,064 shares; and Ms. Chwat - $599,948 for 5,080 shares.
|
(4)
|
The 2015 amounts in this column include the following amounts earned under the 2015 AIP: Mr. Fibig - $607,680; Ms. Cornell - $91,679; Mr. O’Leary - $93,094; Mr. Mirzayantz - $194,320; Mr. Haeni - $192,800; and Ms. Chwat - $117,738.
|
(5)
|
LTIP cycles have four performance segments related to each year in the three-year LTIP cycle and the cumulative results for the full three-year cycle. Any amounts earned under a performance segment are credited on behalf of the executive at the end of the relevant segment, but such credited amounts are not paid until the completion of the three-year LTIP cycle. Upon completion, one-half of any award earned for a completed LTIP cycle is paid in cash and the remaining half is paid in shares of our common stock. The cash portion of the NEOs’ credited awards is reported in this column for the year in which such amount was earned, rather than in the year in which such award is actually paid. The amounts in this column related to 2015 include the amounts earned and credited for the 2015 segment of the 2014-2016 and 2015-2017 LTIP cycles and the following amounts earned for the 2015 and cumulative segments under the completed 2013-2015 LTIP cycle: Mr. Fibig - $509,798; Ms. Cornell - $55,192; Mr. O’Leary - $56,876; Mr. Mirzayantz - $175,781; Mr. Haeni - $65,992; and Ms. Chwat - $108,984.
|
(6)
|
The amounts in this column represent the aggregate change in the actuarial present value of the NEO’s accumulated benefit under our U.S. Pension Plan (our qualified defined benefit plan) and our Supplemental Retirement Plan (our non-qualified defined benefit plan). Earnings in the interest bearing account in the DCP were not above-market, and earnings in other investment choices under the DCP were not preferential, and therefore are not included.
|
(7)
|
Details of the 2015 amounts set forth in this column are included in the All Other Compensation Table.
|
(8)
|
Ms. Cornell was appointed CFO effective July 8, 2015. The amounts in the Salary and Non-Equity Incentive Plan Compensation columns represent prorated amounts based on her partial year of service. The amount in the Bonus column represents the cash bonus paid to Ms. Cornell in connection with her hiring, as further described above in "Compensation Discussion and Analysis - Compensation Setting Process - New Executive Officer Compensation."
|
(9)
|
The amount in the Salary column includes $50,055 of deferred salary that was received three months following the appointment of our new CFO.
|
|
Dividends
on Stock
Awards
($)(1)
|
|
Company
Contributions
to
Savings and
Defined
Contribution
Plans($)(2)
|
|
Auto
($)(3)
|
|
Financial/
Estate
Planning,
Tax
Preparation
and Legal
Services($)
|
|
Executive
Death
Benefit
Program
($)(4)
|
|
Matching
Charitable
Contributions($)
|
|
Relocation
Expenses
($(5)
|
|
Tax
Equalization
/ Assistance
($)(6)
|
|
Other ($)(7)
|
|
Total
($)
|
||||||||||
Andreas Fibig
|
17,502
|
|
|
18,550
|
|
|
61,472
|
|
|
15,222
|
|
|
9,105
|
|
|
—
|
|
|
1,800
|
|
|
120
|
|
|
8,237
|
|
|
133,098
|
|
Alison A. Cornell
|
1,460
|
|
|
3,000
|
|
|
15,698
|
|
|
5,450
|
|
|
2,738
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4,650
|
|
|
32,996
|
|
Richard O’Leary
|
21,628
|
|
|
18,550
|
|
|
11,803
|
|
|
7,500
|
|
|
11,681
|
|
|
2,500
|
|
|
—
|
|
|
—
|
|
|
4,391
|
|
|
78,053
|
|
Nicolas Mirzayantz
|
60,025
|
|
|
55,751
|
|
|
16,010
|
|
|
10,055
|
|
|
12,455
|
|
|
3,500
|
|
|
—
|
|
|
—
|
|
|
11,287
|
|
|
169,083
|
|
Matthias Haeni
|
19,812
|
|
|
90,305(8)
|
|
|
6,746
|
|
|
—
|
|
|
3,900
|
|
|
—
|
|
|
145,458(8)
|
|
|
507,559(8)
|
|
|
8,957
|
|
|
782,736
|
|
Anne Chwat
|
42,156
|
|
|
59,527
|
|
|
15,462
|
|
|
9,836
|
|
|
11,290
|
|
|
10,000
|
|
|
—
|
|
|
—
|
|
|
7,216
|
|
|
155,487
|
|
(1)
|
The amounts in this column represent dividends paid during 2015 on shares of PRS.
|
(2)
|
The amounts in this column represent: (i) matching amounts paid under our Retirement Investment Fund Plan (401(k)); (ii) amounts matched or set aside by our Company under our DCP (which are matching contributions that would otherwise be made under our 401(k) plan but for limitations under U.S. tax law); (iii) the dollar value of premium shares credited to the accounts of participants in the DCP who elect to defer their cash compensation into the IFF Stock Fund; and (iv) for Mr. Haeni, $35,663 contributed to his European retirement plan in lieu of participation in the Company's savings plans and an additional savings allowance of $54,642. The premium shares may be forfeited if the executive does not remain employed by our Company for the full calendar year following the year during which such shares are credited. Dividend equivalents are credited on shares (including premium shares) held in accounts of participants who defer into the IFF Stock Fund. Dividend equivalents are included in the Aggregate Earnings in Last Fiscal Year column of the Non-Qualified Deferred Compensation Table and are not included in the amounts represented in this column.
|
(3)
|
The amounts in this column represent the personal use of automobiles provided by our Company. The value of such use was determined by using standard IRS vehicle value tables and multiplying that value by the percent of personal use. The value of fuel was determined by multiplying the overall fuel cost by the percent of personal use. In both cases personal use percentages were determined on a mileage basis. The amounts in this column also include the cost paid by us for a parking garage and for use of our Company driver.
|
(4)
|
The amounts in this column represent costs for the corporate-owned life insurance coverage we have purchased to offset liabilities that may be incurred under our Executive Death Benefit Program. No participant in this program has or will have any direct interest in the cash surrender value of the underlying insurance policy.
|
(5)
|
The amounts in this column represent (i) for Mr. Fibig, expenses paid in connection with his relocation and (ii) for Mr. Haeni, $1,458 of relocation expenses and an additional $144,000 of living allowance.
|
(6)
|
The amounts in this column represent (i) for Mr. Fibig, the tax gross up o $1,210 on his relocation expenses, and (ii) for Mr. Haeni, a tax gross up of $1,220 on his relocation expenses, a tax equalization payment of $96,623, and a tax gross up of $409,716 on the tax equalization payment.
|
(7)
|
The amounts in this column represent (i) health club membership, (ii) annual physical examination and (iii) amounts paid under our Supplemental Long-Term Disability Plan.
|
(8)
|
In connection with his relocation to the United States, we agreed to provide Mr. Haeni an alternate savings program and certain transitional assistance for the four years following his relocation. In lieu of his participation in our 401(k) plan and DCP, the Company will provide Mr. Haeni an annual savings allowance equal to 11% of his annual base salary as an employer contribution to the Swiss pension plan of his choosing. In addition, the Company will provide (i) a monthly living allowance during 2015 of $12,000, decreasing by $3,000 annually for each subsequent year through 2017, (ii) tax equalization payments (which will be subject to gross-up) during 2015 equal to 75% of the difference in income taxation between Singapore and New York City, decreasing by 25% for each subsequent year through 2017, and (iii) an additional savings allowance during 2015 equal to 75% of the difference between the annual savings allowance and his previous pension payments, decreasing by 25% for each subsequent year through 2017.
|
•
|
Minimum annual base salary of $1,300,000 in 2016;
|
•
|
A target AIP bonus of 120% of his base salary and a potential maximum annual bonus of 240% of his base salary;
|
•
|
An LTIP target of $2,000,000 and a maximum of up to 200% of the LTIP target; and
|
•
|
Participation in the ECP program.
|
Name
|
|
Type of
Award (1)
|
|
Grant Date (2)
|
|
Date of
Compensation
Committee
Approval
|
|
Estimated Future
Payouts Under Non-Equity
Incentive Plan Awards (3)
|
|
Estimated Future
Payouts Under Equity
Incentive Plan Awards (4)
|
|
All Other
Stock
Awards:
Number
of Shares
of Stock
or Units
(#)(5)
|
|
Grant
Date
Fair Value
of
Stock
Awards
($)(6)
|
|||||||||||||||
|
|
|
|
|
|
|
|
Threshold
($)
|
|
Target
($)
|
|
Maximum
($)
|
|
Threshold
($)
|
|
Target
($)
|
|
Maximum
($)
|
|
|
|
|
|||||||
Andreas Fibig
|
|
AIP
|
|
2/9/2015
|
|
2/9/2015
|
|
360,000
|
|
1,440,000
|
|
|
2,880,000
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
2015 LTIP
|
|
2/9/2015
|
|
2/9/2015
|
|
250,000
|
|
1,000,000
|
|
|
2,000,000
|
|
|
250,000
|
|
|
1,000,000
|
|
|
2,000,000
|
|
|
|
|
996,182
|
|
|
|
|
PRS
|
|
5/6/2015
|
|
2/9/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,176
|
|
|
1,319,886
|
|
|||||
|
|
RSU
|
|
5/6/2015
|
|
2/9/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,620
|
|
|
857,098
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Alison A. Cornell
|
|
AIP
|
|
7/8/2015
|
|
5/19/2015
|
|
54,312
|
|
217,249
|
|
|
434,498
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
2015 LTIP
|
|
7/8/2015
|
|
5/19/2015
|
|
51,781
|
|
207,125
|
|
|
414,250
|
|
|
51,781
|
|
|
207,125
|
|
|
414,250
|
|
|
|
|
206,334
|
|
|
|
|
PRSU
|
|
8/17/2015
|
|
5/19/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,608
|
|
|
299,894
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Richard O’Leary
|
|
AIP
|
|
2/9/2015
|
|
2/9/2015
|
|
55,151
|
|
220,603
|
|
|
441,205
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
2015 LTIP
|
|
2/9/2015
|
|
2/9/2015
|
|
24,425
|
|
97,698
|
|
|
195,396
|
|
|
24,425
|
|
|
97,698
|
|
|
195,396
|
|
|
|
|
97,325
|
|
|
|
|
RSU
|
|
1/2/2015
|
|
11/20/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,487(7)
|
|
|
144,388
|
|
|||||
|
|
PRS
|
|
5/6/2015
|
|
2/9/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,540
|
|
|
299,974
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Nicolas Mirzayantz
|
|
AIP
|
|
2/9/2015
|
|
2/9/2015
|
|
120,000
|
|
480,000
|
|
|
960,000
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
2015 LTIP
|
|
2/9/2015
|
|
2/9/2015
|
|
62,500
|
|
250,000
|
|
|
500,000
|
|
|
62,500
|
|
|
250,000
|
|
|
500,000
|
|
|
|
|
249,046
|
|
|
|
|
PRS
|
|
5/6/2015
|
|
2/9/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,112
|
|
|
839,927
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Matthias Haeni
|
|
AIP
|
|
2/9/2015
|
|
2/9/2015
|
|
100,000
|
|
400,000
|
|
|
800,000
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
2015 LTIP
|
|
2/9/2015
|
|
2/9/2015
|
|
62,500
|
|
250,000
|
|
|
500,000
|
|
|
62,500
|
|
|
250,000
|
|
|
500,000
|
|
|
|
|
249,046
|
|
|
|
|
PRS
|
|
5/6/2015
|
|
2/9/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,064
|
|
|
479,958
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Anne Chwat
|
|
AIP
|
|
2/9/2015
|
|
2/9/2015
|
|
69,750
|
|
279,000
|
|
|
558,000
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
2015 LTIP
|
|
2/9/2015
|
|
2/9/2015
|
|
34,875
|
|
139,500
|
|
|
279,000
|
|
|
34,875
|
|
|
139,500
|
|
|
279,000
|
|
|
|
|
138,967
|
|
|
|
|
PRS
|
|
5/6/2015
|
|
2/9/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,080
|
|
|
599,948
|
|
(1)
|
AIP = 2015 AIP
|
(2)
|
All equity, AIP and LTIP grants were made under our 2015 SAIP. The material terms of these types of awards are described in this proxy statement under the heading “Compensation Discussion and Analysis.”
|
(3)
|
AIP amounts in this column are the threshold, target and maximum dollar values under our 2015 AIP. 2015 LTIP amounts in this column are the threshold, target and maximum dollar values of the 50% portion of our 2015-2017 LTIP cycle that would be payable in cash if the performance conditions are satisfied.
|
(4)
|
2015 LTIP amounts in this column are the threshold, target and maximum dollar values of the 50% portion of our 2015-2017 LTIP cycle that would be payable in stock if the performance conditions are satisfied. The number of shares of our common stock for the 50% portion payable in stock was determined at the beginning of the 2015 LTIP cycle, based on $102.14 per share, the average closing market price of a share of our common stock for the 20 trading days preceding January 1, 2015, the first trading day of the 2015-2017 LTIP cycle (except for Ms. Cornell's stock portion which was based on $111.19 per share, the average closing market price for the 20 trading days preceding July 8, 2015). However, the actual value to be realized may vary depending on the closing market price of a share of our common stock on the payout date of 2015 LTIP awards.
|
(5)
|
The amounts in this column represent the number of PRS shares or PRSUs granted under the ECP in 2015 on the grant date. Dividends are paid on PRS shares. Footnote 4 to the Summary Compensation Table states the dollar amount delivered by our NEOs (in tendered shares or cash) for these PRS awards. The material terms of the ECP awards are described in this proxy statement under the heading “Compensation Discussion & Analysis.”
|
(6)
|
The amounts in this column represent the aggregate grant date fair value of equity awards granted to our NEOs during the fiscal year ended December 31, 2015, calculated in accordance with FASB ASC Topic 718. The grant date fair value of LTIP awards pertains to the 50% portion of those awards that will be payable in shares of our common stock if the performance conditions are satisfied, and is based on the probable outcome of such conditions.
|
(7)
|
This award represents a grant of RSUs to Mr. O'Leary for acting as Interim Chief Financial Officer.
|
|
Segment I
(2013)
|
|
Segment 2
(2014)
|
|
Segment 3
(2015)
|
|
Cumulative
(2013 – 2015)
|
|
Total
|
||||||||||||||||||||
|
Cash
($)
|
|
Shares
(#)
|
|
Cash
($)
|
|
Shares
(#)
|
|
Cash
($)
|
|
Shares
(#)
|
|
Cash
($)
|
|
Shares
(#)
|
|
Cash
($)
|
|
Shares
(#)
|
||||||||||
Andreas Fibig (1)
|
—
|
|
|
—
|
|
|
102,265
|
|
|
1,021
|
|
|
292,500
|
|
|
2,921
|
|
|
217,298
|
|
|
2,172
|
|
|
612,063
|
|
|
6,114
|
|
Alison A. Cornell (2)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
35,458
|
|
|
319
|
|
|
19,734
|
|
|
176
|
|
|
55,192
|
|
|
495
|
|
Richard O’Leary
|
24,350
|
|
|
369
|
|
|
22,276
|
|
|
338
|
|
|
21,293
|
|
|
323
|
|
|
35,583
|
|
|
540
|
|
|
103,502
|
|
|
1,570
|
|
Nicolas Mirzayantz
|
75,263
|
|
|
1,141
|
|
|
68,850
|
|
|
1,044
|
|
|
65,813
|
|
|
998
|
|
|
109,969
|
|
|
1,668
|
|
|
319,895
|
|
|
4,851
|
|
Matthias Haeni
|
28,255
|
|
|
428
|
|
|
25,848
|
|
|
392
|
|
|
24,708
|
|
|
374
|
|
|
41,285
|
|
|
628
|
|
|
120,096
|
|
|
1,822
|
|
Anne Chwat
|
46,663
|
|
|
708
|
|
|
42,687
|
|
|
647
|
|
|
40,804
|
|
|
619
|
|
|
68,181
|
|
|
1,032
|
|
|
198,335
|
|
|
3,006
|
|
|
Segment 2
(2015)
|
|||
|
Cash
($)
|
Shares
(#)
|
||
Andreas Fibig
|
292,500
|
|
2,921
|
|
Alison A. Cornell (1)
|
35,458
|
|
319
|
|
Richard O’Leary
|
21,995
|
|
257
|
|
Nicolas Mirzayantz
|
73,125
|
|
855
|
|
Matthias Haeni
|
73,125
|
|
855
|
|
Anne Chwat
|
40,804
|
|
477
|
|
|
Segment 1
(2015)
|
|||
|
Cash
($)
|
Shares
(#)
|
||
Andreas Fibig
|
292,500
|
|
2,864
|
|
Alison A. Cornell (1)
|
35,458
|
|
319
|
|
Richard O’Leary
|
28,576
|
|
280
|
|
Nicolas Mirzayantz
|
73,125
|
|
716
|
|
Matthias Haeni
|
73,125
|
|
716
|
|
Anne Chwat
|
40,804
|
|
399
|
|
Plan Category
|
|
Number of
securities to be
issued upon
exercise of
outstanding
options,
warrants and
rights
|
|
Weighted-average
exercise price of
outstanding options,
warrants and rights
|
|
Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding
securities reflected in
column (a))
|
|
|||
|
|
(a)
|
|
(b)
|
|
(c)
|
|
|||
Equity compensation plans approved by security holders (1)
|
|
843,326
|
|
(2)
|
52.59
|
|
(3)
|
2,547,132
|
|
|
Equity compensation plans not approved by security holders (4)
|
|
204,433
|
|
|
52.59
|
|
(3)
|
229,995
|
|
(5)
|
Total
|
|
1,047,759
|
|
|
52.59
|
|
(3)
|
2,777,127
|
|
|
(1)
|
Represents the 2015 Stock Award and Incentive Plan (the “2015 SAIP”). The 2015 Plan replaced the Company’s 2010 Stock Award and Incentive Plan (the “2010 Plan”) and provides the source for future deferrals of cash into deferred stock under the Company’s Deferred Compensation Plan (with the Deferred Compensation Plan being deemed a subplan under the 2010 Plan for the sole purpose of funding deferrals under the IFF Share Fund).
|
(2)
|
Includes options, RSUs, SSARs, the number of shares to be issued under the 2013-2015 LTIP cycle based on actual performance, and the maximum number of shares that may be issued under the 2014-2016 and 2015-2017 LTIP cycles if the performance conditions for each of those cycles are satisfied at the maximum level. The number of SSARs that may be issued upon exercise was calculated by dividing (i) the product of (a) the excess of the closing market price of our common stock on the last trading day of 2015 over the exercise price, and (b) the number of SSARs outstanding by (ii) the closing market price on the last trading day of 2015. Excludes outstanding shares of PRS under the 2010 SAIP and 2000 SAIP.
|
(3)
|
Weighted average exercise price of outstanding options and SSARs. Excludes RSUs, shares credited to accounts of participants in the DCP and shares that may be issued under the 2013-2015 and 2014-2016 LTIP cycles.
|
(4)
|
We currently have two equity compensation plans that have not been approved by our shareholders: (i) the DCP, which is described on page 46 and (ii) a pool of shares that may be used for annual awards of 1,000 shares to each non-employee director. Although we are no longer granting these annual 1,000 share stock awards to directors, the pool of shares remains authorized.
|
(5)
|
Includes 186,245 shares remaining available for issuance under the DCP and 43,750 shares remaining available for issuance from a pool of shares that may be used for annual awards of 1,000 shares to each non-employee director.
|
Name
|
|
Grant Date
|
|
Grant Type (1)
|
|
Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)
|
|
Market Value
of Shares or
Units of Stock
That Have Not
Vested
($)(2)
|
|
Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other Rights
That Have
Not Vested
(#)
|
|
Equity
Incentive Plan
Awards: Market
or Payout
Value of
Unearned
Shares,
Units or
Other Rights
That Have
Not Vested
($)(2)
|
||||
Andreas Fibig
|
|
4/30/2013
|
|
RSU
|
|
1,295
|
|
(3)
|
154,934
|
|
|
—
|
|
|
—
|
|
|
|
9/1/2014
|
|
2014 LTIP
|
|
3,942
|
|
(4)
|
471,657
|
|
|
8,886
|
|
(5)
|
1,063,121
|
|
|
|
2/11/2015
|
|
2015 LTIP
|
|
2,864
|
|
(6)
|
342,668
|
|
|
14,684
|
|
(7)
|
1,756,794
|
|
|
|
10/15/2014
|
|
RSU
|
|
7,967
|
|
(8)
|
953,172
|
|
|
—
|
|
|
—
|
|
|
|
5/6/2015
|
|
RSU
|
|
7,620
|
|
(9)
|
911,657
|
|
|
—
|
|
|
—
|
|
|
|
5/6/2015
|
|
PRS
|
|
11,176
|
|
(9)
|
1,337,097
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Alison A. Cornell
|
|
7/8/2015
|
|
2014 LTIP
|
|
319
|
|
(4)
|
38,214
|
|
|
1,682
|
|
(5)
|
201,234
|
|
|
|
7/8/2015
|
|
2015 LTIP
|
|
319
|
|
(6)
|
38,214
|
|
|
3,180
|
|
(7)
|
380,455
|
|
|
|
8/17/2015
|
|
PRSU
|
|
2,608
|
|
(10)
|
312,021
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Richard O’Leary
|
|
4/30/2013
|
|
PRS
|
|
3,109
|
|
(11)
|
371,961
|
|
|
—
|
|
|
—
|
|
|
|
2/5/2014
|
|
2014 LTIP
|
|
526
|
|
(4)
|
62,892
|
|
|
878
|
|
(5)
|
105,044
|
|
|
|
5/13/2014
|
|
PRS
|
|
2,749
|
|
(12)
|
328,890
|
|
|
—
|
|
|
—
|
|
|
|
1/2/2015
|
|
RSU
|
|
1,487
|
|
(13)
|
177,905
|
|
|
—
|
|
|
—
|
|
|
|
2/11/2015
|
|
2015 LTIP
|
|
280
|
|
(6)
|
33,455
|
|
|
1,436
|
|
(7)
|
171,803
|
|
|
|
5/6/2015
|
|
PRS
|
|
2,540
|
|
(9)
|
303,886
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Nicolas Mirzayantz
|
|
4/30/2013
|
|
PRS
|
|
9,327
|
|
(11)
|
1,115,882
|
|
|
—
|
|
|
—
|
|
|
|
2/5/2014
|
|
2014 LTIP
|
|
1,750
|
|
(4)
|
209,372
|
|
|
2,924
|
|
(5)
|
349,827
|
|
|
|
5/13/2014
|
|
PRS
|
|
7,943
|
|
(12)
|
950,301
|
|
|
—
|
|
|
—
|
|
|
|
6/13/2014
|
|
RSU
|
|
20,000
|
|
(14)
|
2,392,800
|
|
|
—
|
|
|
—
|
|
|
|
2/11/2015
|
|
2015 LTIP
|
|
716
|
|
(6)
|
85,667
|
|
|
3,672
|
|
(7)
|
439,318
|
|
|
|
5/6/2015
|
|
PRS
|
|
7,112
|
|
(9)
|
850,880
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Matthias Haeni
|
|
4/30/2013
|
|
PRS
|
|
1,922
|
|
(11)
|
229,948
|
|
|
—
|
|
|
—
|
|
|
|
2/5/2014
|
|
2014 LTIP
|
|
1,750
|
|
(4)
|
209,372
|
|
|
2,924
|
|
(5)
|
349,827
|
|
|
|
5/13/2014
|
|
PRS
|
|
3,666
|
|
(12)
|
438,600
|
|
|
—
|
|
|
—
|
|
|
|
2/11/2015
|
|
2015 LTIP
|
|
716
|
|
(6)
|
85,667
|
|
|
3,672
|
|
(7)
|
439,318
|
|
|
|
5/6/2015
|
|
PRS
|
|
4,064
|
|
(9)
|
486,217
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Anne Chwat
|
|
4/30/2013
|
|
PRS
|
|
6,607
|
|
(11)
|
790,461
|
|
|
—
|
|
|
—
|
|
|
|
2/5/2014
|
|
2014 LTIP
|
|
976
|
|
(4)
|
116,739
|
|
|
1,630
|
|
(5)
|
195,013
|
|
|
|
5/13/2014
|
|
PRS
|
|
5,499
|
|
(12)
|
657,900
|
|
|
—
|
|
|
—
|
|
|
|
2/11/2015
|
|
2015 LTIP
|
|
399
|
|
(6)
|
47,733
|
|
|
2,050
|
|
(7)
|
245,262
|
|
|
|
5/6/2015
|
|
PRS
|
|
5,080
|
|
(9)
|
607,771
|
|
|
—
|
|
|
—
|
|
(1)
|
2014 LTIP = 2014-2016 Long-Term Incentive Plan Cycle
|
(2)
|
The market value was determined based on the closing price of our common stock on December 31, 2015. For PRS and PRSU awards, the amounts in this column do not reflect the purchase price paid by the NEO for PRS shares under the ECP as described in the Compensation Discussion and Analysis.
|
(3)
|
This award was granted to Mr. Fibig as a non-employee director and vests on April 30, 2016.
|
(4)
|
This amount represents the number of shares of stock that have been credited for the 2014 and 2015 segment of the 2014-2016 LTIP cycle. These shares will remain unvested until the completion of the full three-year LTIP cycle.
|
(5)
|
This amount represents the maximum number of shares of stock that remain subject to the achievement of specified performance objectives over the remaining two open segments of the 2014-2016 LTIP cycle. Shares earned during any segment of the 2014-2016 LTIP cycle will remain unvested until the completion of the full three-year cycle.
|
(6)
|
This amount represents the number of shares of stock that have been credited for the 2015 segment of the 2015-2017 LTIP cycle. These shares will remain unvested until the completion of the full three-year LTIP cycle.
|
(7)
|
This amount represents the maximum number of shares of stock that remain subject to the achievement of specified performance objectives over the remaining three open segments of the 2015-2017 LTIP cycle. Shares earned during any segment of the 2015-2017 LTIP cycle will remain unvested until the completion of the full three-year cycle.
|
(8)
|
This award vests on April 13, 2017.
|
(9)
|
This award vests on April 6, 2018.
|
(10)
|
This award vests on July 17, 2018.
|
(11)
|
This award vests on March 31, 2016.
|
(12)
|
This award vests on April 13, 2017.
|
(13)
|
This award vests on January 2, 2017.
|
(14)
|
This award vests on June 13, 2016.
|
|
|
Stock Awards
|
||||||
Name
|
|
Type of Award(1)
|
|
Number of Shares
Acquired on
Vesting (#)
|
|
Value Realized on
Vesting ($)
|
||
Andreas Fibig
|
|
RSU
|
(2)
|
1,655
|
|
|
194,330
|
|
|
|
RSU
|
(3)
|
1,145
|
|
|
129,030
|
|
|
|
PRS
|
(4)(5)
|
6,373
|
|
|
745,450
|
|
|
|
2013 LTIP
|
(6)
|
6,114
|
|
|
731,479
|
|
|
|
|
|
|
|
|
||
Alison A. Cornell
|
|
2013 LTIP
|
(6)
|
495
|
|
|
67,617
|
|
|
|
|
|
|
|
|
||
Richard O’Leary
|
|
PRS
|
(4)(5)
|
7,948
|
|
|
689,688
|
|
|
|
2013 LTIP
|
(6)
|
1,570
|
|
|
187,835
|
|
|
|
|
|
|
|
|
||
Nicolas Mirzayantz
|
|
PRS
|
(4)(5)
|
19,870
|
|
|
1,724,219
|
|
|
|
2013 LTIP
|
(6)
|
4,851
|
|
|
580,374
|
|
|
|
|
|
|
|
|
||
Matthias Haeni
|
|
PRS
|
(4)(5)
|
4,912
|
|
|
426,239
|
|
|
|
2013 LTIP
|
(6)
|
1,822
|
|
|
217,984
|
|
|
|
|
|
|
|
|
||
Anne Chwat
|
|
RSU
|
(7)
|
250
|
|
|
27,160
|
|
|
|
PRS
|
(4)(5)
|
13,909
|
|
|
1,206,953
|
|
|
|
2013 LTIP
|
(6)
|
3,006
|
|
|
359,638
|
|
(1)
|
RSU = Restricted Stock Unit
|
(2)
|
The award represented in this row was granted in 2012 to Mr. Fibig while he was a member of the Board of Directors and vested on May 1, 2015. The value realized is based on the closing price of our common stock on the vesting date ($117.42).
|
(3)
|
The award represented in this row was granted in 2014 to Mr. Fibig while he was a member of the Board of Directors and vested on May 13, 2015. The value realized is based on the closing price of our common stock on the vesting date ($112.69).
|
(4)
|
The award represented in this row was granted in 2012 under the ECP and vested on April 1, 2015. The value realized is based on the closing price of our common stock on the vesting date ($116.97).
|
(5)
|
The amounts set forth in this table as the value realized attributable to vested PRS is the product of (a) the number of vested shares of PRS and (b) the closing price of our common stock on the vesting date, less the aggregate amount paid by the executive to purchase the PRS. Without taking into account the amount paid by the respective executive for his or her PRS shares, the value realized on vesting in the Value Realized on Vesting column attributable to PRS for this executive would be: Mr. Fibig - $745,450; Mr. O’Leary - $929,678; Mr. Mirzayantz - $2,324,194; Mr. Haeni - $574,557; and Ms. Chwat - $1,626,936.
|
(6)
|
The award represented in this row is the equity portion of the 2013-2015 LTIP award, for which performance was completed on December 31, 2015. The number of shares represents the actual number of shares that will be issued to the participant in March 2016, as determined by the Board of Directors in February 2016. The value realized is based on the number of shares and the closing market price of a share of our common stock on December 31, 2015 ($119.64); however, the actual value realized may vary depending on the closing market price of a share of our common stock on the payout date.
|
(7)
|
This award represents a special recognition award of RSUs to Ms. Chwat in connection with the Aromor acquisition. The value realized is based on the closing price of our common stock on the vesting date of February 2, 2015 ($106.78).
|
Name
|
|
Plan Name
|
|
Number
of Years
Credited
Service
(#)
|
|
Present
Value of
Accumulated
Benefits
Assuming
Retirement
Age of 62
($)(1)
|
|
Present
Value of
Accumulated
Benefits
Assuming
Retirement
Age of 65
($)(2)
|
|
Payments
During
Last
Fiscal
Year ($)
|
||||
Nicolas Mirzayantz (3)
|
|
U.S. Pension Plan
|
|
16.23
|
|
|
542,078
|
|
|
450,062
|
|
|
—
|
|
|
|
Supplemental Retirement Plan
|
|
16.23
|
|
|
863,751
|
|
|
717,132
|
|
|
—
|
|
|
|
|
|
|
|
1,405,829
|
|
|
1,167,194
|
|
|
—
|
|
(1)
|
The amounts in this column assume benefit commencement at unreduced early retirement at age 62 (with at least 10 years of credited service) and otherwise were determined using interest rate, mortality and payment distribution assumptions consistent with those used in our financial statements.
|
(2)
|
The amounts in this column assume benefit commencement at normal retirement at age 65 and otherwise were determined using interest rate, mortality and payment distribution assumptions consistent with those used in our financial statements.
|
(3)
|
Benefits for Mr. Mirzayantz under the U.S. Pension Plan and Supplemental Retirement Plan were frozen as of December 31, 2007 because his age and service as of December 31, 2007 did not equal or exceed 70.
|
Name
|
|
Executive
Contributions
in Last FY ($)
|
|
Registrant
Contributions
in Last FY
($)(1)
|
|
Aggregate
Earnings
in Last
FY ($)
|
|
Aggregate
Withdrawals/
Distributions ($)
|
|
Aggregate
Balance at
Last FYE
($)(2)
|
|||||
Andreas Fibig
|
|
194,330
|
|
|
—
|
|
|
49,952
|
|
|
—
|
|
|
754,171
|
|
Alison A. Cornell
|
|
81,667
|
|
(3)
|
—
|
|
|
84
|
|
|
—
|
|
|
81,803
|
|
Richard O’Leary
|
|
—
|
|
|
—
|
|
|
21,369
|
|
|
—
|
|
|
129,646
|
|
Nicolas Mirzayantz
|
|
217,562
|
|
(4)
|
37,201
|
|
|
52,608
|
|
|
—
|
|
|
1,678,204
|
|
Matthias Haeni
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Anne Chwat
|
|
210,394
|
|
(5)
|
40,977
|
|
|
155,507
|
|
|
—
|
|
|
1,684,961
|
|
(1)
|
The amounts in this column are included in the All Other Compensation column for 2015 in the Summary Compensation Table, and represent employer contributions credited to the participant’s account during 2015, as well as certain contributions credited in the first quarter of 2016 related to compensation earned in 2015.
|
(2)
|
If a person was a NEO in previous years’ proxy statements, this amount includes amounts that were included as compensation previously reported for that person in the Summary Compensation Table for those previous years. Of the totals in this column, the following amounts were reported as compensation in the Summary Compensation Table for 2006: Mr. Mirzayantz – $87,985; for 2007: Mr. Mirzayantz – $160,010; for 2008: Mr. Mirzayantz – $63,269; for 2009: Mr. Mirzayantz – $31,228; for 2010: Mr. Mirzayantz – $243,228; for 2011: Mr. Mirzayantz – $45,600; Ms. Chwat – $316,928; for 2012: Mr. Mirzayantz – $516,144; Ms. Chwat – $398,970; for 2013: Mr. Mirzayantz – $751,443; Ms. Chwat – $509,236; and for 2014: Mr. Fibig – $443,624; Mr. O'Leary – $161,002; Mr. Mirzayantz – $500,852; Ms. Chwat – $305,561.
|
(3)
|
This amount is included in the Salary column for 2015 in the Summary Compensation Table.
|
(4)
|
Of this amount, $58,500 is included in the Salary column for 2015 in the Summary Compensation Table. Mr. Mirzayantz also deferred $159,062 which is a portion of his AIP and was included in the Non-Equity Incentive Plan Compensation column for 2014 in the Summary Compensation Table.
|
(5)
|
Of this amount, $139,500 is included in the Salary column for 2015 in the Summary Compensation Table. Ms. Chwat also deferred $70,894 which is a portion of her AIP and was included in the Non-Equity Incentive Plan Compensation column for 2014 in the Summary Compensation Table.
|
(i)
|
a person or group becomes the beneficial owner of 40% or more of the combined voting power of our then outstanding voting securities, other than beneficial ownership by us, any of our employee benefit plans or any person organized, appointed or established pursuant to the terms of any such benefit plan;
|
(ii)
|
individuals who, at March 9, 2015, constituted a majority of the Board (the “Incumbent Directors”) cease to constitute a majority of the Board for any reason; provided, however, that any individual becoming a director subsequent to March 9, 2015 whose election or nomination for election to the Board was approved by a vote of at least two-thirds of the Incumbent Directors then on the Board shall be an Incumbent Director; or
|
(iii)
|
the consummation of (A) a merger, consolidation, reorganization or similar transaction with us or in which our securities are issued, as a result of which the holders of our outstanding voting securities immediately before such event own, directly or indirectly, immediately after such event less than 60% of the combined voting power of the outstanding voting securities of the parent entity resulting from, or issuing its voting securities as part of, such event; (B) our complete liquidation or dissolution; or (C) a sale or other disposition of all or substantially all of our assets to any person.
|
(i)
|
A severance payment equal to (a) one and a half times (1.5x) in case of our Tier I executives, and (b) one times (1x) in case of our Tier II executives, the sum of the executive's annual base salary at the date of termination plus the prorated portion of the executive's target AIP award for the year in which termination occurs (payable to the Tier I or Tier II executive in regular installments over 18 or 12 months, respectively, following termination);
|
(ii)
|
A prorated portion of the executive’s target AIP award for the year in which termination occurs, payable when such AIP amounts otherwise become payable;
|
(iii)
|
A prorated portion of the executive’s target LTIP award for the cycles then in progress, payable when such LTIP amounts otherwise become payable;
|
(iv)
|
Vesting of a prorated portion of any unvested equity award(s); and
|
(v)
|
Continuation of medical, dental, disability and life insurance coverage for 18 months years in the case of our Tier I executives and 12 months for Tier II executives or until the executive obtains new employment providing similar benefits or attains age 65.
|
(i)
|
A severance payment equal to two times (2x) in case of our Tier I executives, and one and a half times (1.5x) in case of our Tier II executives, the sum of the executive’s annual base salary at the date of termination plus the higher of (x) his or her average AIP award for the three most recent years and (y) his or her target AIP award for the year in which termination occurs, payable in a lump sum;
|
(ii)
|
A prorated portion of the executive’s target AIP award for the year in which termination occurs, payable in a lump sum;
|
(iii)
|
For each performance segment that ended prior to the termination, a payment equal to the LTIP award payment the executive would have been entitled to receive for such performance segment had the termination not occurred, payable in a lump sum;
|
(iv)
|
For each performance segment in which the executive’s date of termination occurs, a prorated portion of the executive’s target LTIP award for each performance segment in which the termination occurs, payable in a lump sum;
|
(v)
|
Vesting of any equity awards not already vested upon the CiC and, unless deferred by the executive, settlement of such equity awards;
|
(vi)
|
Vesting of any benefits under our Supplemental Retirement Plan; and
|
(vii)
|
Continuation of medical, dental, disability and life insurance coverage for 18 months for our Tier I executives, and 12 months for our Tier II executives or until the executive obtains new employment providing similar benefits or attains age 65.
|
•
|
"Cause" means (i) failure of the executive to perform his or her material duties in any material respect, which if reasonably susceptible to cure, has continued after written notice of such failure has been provided and the executive has not cured such failure within 10 days of receipt of such written notice; (ii) willful misconduct or gross negligence by the executive that has caused or is reasonably expected to result in material injury to our business, reputation, or prospects; (iii) the engagement by the executive in illegal conduct or any act of serious dishonesty which could reasonably be expected to result in material injury to our business or reputation or which adversely affects the executive’s ability to perform his or her duties; (iv) the executive being indicted or convicted of (or having pled guilty or nolo contendere to) a felony or any crime involving moral turpitude, dishonesty, fraud, theft or financial impropriety; or (v) a material and willful violation by the executive of our rules, policies or procedures.
|
•
|
“Good Reason” means any of the following: (i) a material decrease in the executive’s base salary, target bonus under an AIP, LTIP or Equity Choice Award, other than as part of an across-the-board reduction applicable to all similarly situated employees; (ii) a material diminution in the executive’s authority, duties or responsibilities; (iii) relocation of executive’s primary work location more than 50 miles from executive’s primary work location at the time of such requested relocation; or (iv) our failure to obtain the binding agreement of any successor expressly to assume and agree to fully perform our obligations under the ESP. However, “good reason” will only exist if the executive gives us notice within 90 days after the initial occurrence of any of the foregoing events and we fail to correct the matter within 30 days following receipt of such notice.
|
(i)
|
In connection with any termination without Cause or for Good Reason, not in connection with a CiC:
|
a.
|
Mr. Fibig’s severance payment will be a multiple of two times (2x) the sum of his annual base salary plus the average AIP bonus paid to him in the three years prior to termination, payable over 24 months; and
|
b.
|
Mr. Fibig will be entitled to receive a pro-rated portion of any LTIP award that is in progress on the date of termination, based on target, in a lump-sum cash payment.
|
(ii)
|
Mr. Fibig’s severance payment in connection with any termination without Cause or for Good Reason that occurs within two years after a CiC will be a multiple of three times (3x) the sum of his annual base salary plus the greater of his (a) target AIP award for the year of termination and (b) the average AIP award paid to him for the three fiscal years prior to the termination, and such payments will be payable in a lump sum. In addition, all of Mr. Fibig's outstanding equity awards will vest in full at target;
|
(iii)
|
Mr. Fibig will be entitled to continuation of medical, dental, disability and life insurance coverage for 24 months in the case of termination without Cause or for Good Reason, whether or not in connection with a CiC.
|
|
Involuntary
Termination
Not for
Cause or Good Reason Prior
to or More
Than 2 Years
After a CiC
|
|
Termination
due to Death(1)
|
|
Separation
Due to
Retirement
or Disability
Prior to or
More Than
2 Years
After a CiC(2)
|
|
Not for Cause or
Good Reason
Termination
Within 2 Years
After a CiC
|
|
Separation
Due to
Retirement or
Disability
Within 2
Years
After a CiC(2)
|
||||||||||
Andreas Fibig
|
|
|
|
|
|
|
|
|
|
||||||||||
Salary
|
$
|
2,400,000
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
3,600,000
|
|
(3)
|
$
|
—
|
|
AIP
|
2,880,000
|
|
(4)
|
—
|
|
|
—
|
|
|
4,320,000
|
|
(5)
|
—
|
|
|||||
LTIP (6)
|
771,807
|
|
|
771,807
|
|
|
771,807
|
|
|
771,807
|
|
|
771,807
|
|
|||||
ECP Acceleration (7)
|
2,018,851
|
|
|
5,480,589
|
|
|
—
|
|
|
5,480,589
|
|
|
5,480,589
|
|
|||||
Medical Benefits (8)
|
58,990
|
|
|
—
|
|
|
—
|
|
|
58,990
|
|
|
—
|
|
|||||
Executive Death Benefit (9)
|
—
|
|
|
2,400,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Executive Death Benefit Cost (10)
|
16,471
|
|
|
—
|
|
|
—
|
|
|
24,706
|
|
|
—
|
|
|||||
Disability Insurance (11)
|
—
|
|
|
—
|
|
|
180,000
|
|
|
—
|
|
|
180,000
|
|
|||||
Total
|
$
|
8,146,119
|
|
|
$
|
8,652,396
|
|
|
$
|
951,807
|
|
|
$
|
14,256,092
|
|
|
$
|
6,432,396
|
|
Alison A. Cornell
|
|
|
|
|
|
|
|
|
|
||||||||||
Salary
|
$
|
840,000
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,120,000
|
|
|
$
|
—
|
|
AIP
|
325,874
|
|
(4)
|
—
|
|
|
—
|
|
|
900,000
|
|
(5)
|
—
|
|
|||||
LTIP (6)
|
42,626
|
|
|
42,626
|
|
|
42,626
|
|
|
42,626
|
|
|
42,626
|
|
|||||
ECP Acceleration (7)
|
85,756
|
|
|
357,932
|
|
|
—
|
|
|
357,932
|
|
|
357,932
|
|
|||||
Medical Benefits (8)
|
13,571
|
|
|
—
|
|
|
—
|
|
|
13,571
|
|
|
—
|
|
|||||
Executive Death Benefit (9)
|
—
|
|
|
1,120,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Executive Death Benefit Cost (10)
|
339
|
|
|
—
|
|
|
—
|
|
|
453
|
|
|
—
|
|
|||||
Disability Insurance (11)
|
—
|
|
|
—
|
|
|
180,000
|
|
|
—
|
|
|
180,000
|
|
|||||
Total
|
$
|
1,308,166
|
|
|
$
|
1,520,558
|
|
|
$
|
222,626
|
|
|
$
|
2,434,582
|
|
|
$
|
580,558
|
|
Richard O’Leary
|
|
|
|
|
|
|
|
|
|
||||||||||
Salary
|
$
|
400,000
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
600,000
|
|
|
$
|
—
|
|
AIP
|
220,603
|
|
(4)
|
—
|
|
|
—
|
|
|
330,904
|
|
(5)
|
—
|
|
|||||
LTIP (6)
|
86,870
|
|
|
86,870
|
|
|
86,870
|
|
|
86,870
|
|
|
86,870
|
|
|||||
ECP Acceleration (7)
|
780,607
|
|
|
1,296,728
|
|
|
—
|
|
|
1,296,728
|
|
|
1,296,728
|
|
|||||
Medical Benefits (8)
|
29,495
|
|
|
—
|
|
|
—
|
|
|
29,495
|
|
|
—
|
|
|||||
Executive Death Benefit (9)
|
—
|
|
|
800,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Executive Death Benefit Cost (10)
|
7,912
|
|
|
—
|
|
|
—
|
|
|
11,868
|
|
|
—
|
|
|||||
Disability Insurance (11)
|
—
|
|
|
—
|
|
|
180,000
|
|
|
—
|
|
|
180,000
|
|
|||||
Total
|
$
|
1,525,487
|
|
|
$
|
2,183,598
|
|
|
$
|
266,870
|
|
|
$
|
2,355,865
|
|
|
$
|
1,563,598
|
|
Nicolas Mirzayantz
|
|
|
|
|
|
|
|
|
|
||||||||||
Salary
|
$
|
900,000
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,200,000
|
|
|
—
|
|
|
AIP
|
720,000
|
|
(4)
|
—
|
|
|
—
|
|
|
1,120,037
|
|
(5)
|
—
|
|
|||||
LTIP (6)
|
263,886
|
|
|
263,886
|
|
|
263,886
|
|
|
263,886
|
|
|
263,886
|
|
|||||
ECP Acceleration (7)
|
3,904,113
|
|
|
5,660,181
|
|
|
—
|
|
|
5,660,181
|
|
|
5,660,181
|
|
|||||
Medical Benefits (8)
|
44,243
|
|
|
—
|
|
|
—
|
|
|
44,243
|
|
|
—
|
|
|||||
Executive Death Benefit (9)
|
—
|
|
|
1,200,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Executive Death Benefit Cost (10)
|
8,741
|
|
|
—
|
|
|
—
|
|
|
11,655
|
|
|
—
|
|
|||||
Disability Insurance (11)
|
—
|
|
|
—
|
|
|
180,000
|
|
|
—
|
|
|
180,000
|
|
|||||
Total
|
$
|
5,840,983
|
|
|
$
|
7,124,067
|
|
|
$
|
443,886
|
|
|
$
|
8,300,002
|
|
|
$
|
6,104,067
|
|
|
Involuntary
Termination
Not for
Cause Prior
to or More
Than 2 Years
After a CiC
|
|
Termination
due to Death(1)
|
|
Separation
Due to
Retirement
or Disability
Prior to or
More Than
2 Years
After a CiC(2)
|
|
Not For Cause or
Good Reason
Termination
Within 2 Years
After a CiC
|
|
Separation
Due to
Retirement or
Disability
Within 2
Years
After a CiC(2)
|
||||||||||
Matthias Haeni
|
|
|
|
|
|
|
|
|
|
||||||||||
Salary
|
$
|
750,000
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,000,000
|
|
|
$
|
—
|
|
AIP
|
600,000
|
|
(4)
|
—
|
|
|
—
|
|
|
800,000
|
|
(5)
|
—
|
|
|||||
LTIP (6)
|
263,886
|
|
|
263,886
|
|
|
263,886
|
|
|
263,886
|
|
|
263,886
|
|
|||||
ECP Acceleration (7)
|
902,800
|
|
|
1,505,084
|
|
|
—
|
|
|
1,505,084
|
|
|
1,505,084
|
|
|||||
Medical Benefits (8)
|
19,647
|
|
|
—
|
|
|
—
|
|
|
19,647
|
|
|
—
|
|
|||||
Executive Death Benefit (9)
|
—
|
|
|
1,000,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Executive Death Benefit Cost (10)
|
339
|
|
|
—
|
|
|
—
|
|
|
453
|
|
|
—
|
|
|||||
Disability Insurance (11)
|
—
|
|
|
|
|
180,000
|
|
|
—
|
|
|
180,000
|
|
||||||
Total
|
$
|
2,536,672
|
|
|
$
|
2,768,970
|
|
|
$
|
443,886
|
|
|
$
|
3,589,070
|
|
|
$
|
1,948,970
|
|
Anne Chwat
|
|
|
|
|
|
|
|
|
|
||||||||||
Salary
|
$
|
697,500
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
930,000
|
|
|
$
|
—
|
|
AIP
|
418,500
|
|
(4)
|
—
|
|
|
—
|
|
|
679,775
|
|
(5)
|
—
|
|
|||||
LTIP (6)
|
147,248
|
|
|
147,248
|
|
|
147,248
|
|
|
147,248
|
|
|
147,248
|
|
|||||
ECP Acceleration (7)
|
1,393,191
|
|
|
2,251,503
|
|
|
—
|
|
|
2,251,503
|
|
|
2,251,503
|
|
|||||
Medical Benefits (8)
|
44,243
|
|
|
—
|
|
|
—
|
|
|
44,243
|
|
|
—
|
|
|||||
Executive Death Benefit (9)
|
—
|
|
|
930,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Executive Death Benefit Cost (10)
|
11,984
|
|
|
—
|
|
|
—
|
|
|
17,976
|
|
|
—
|
|
|||||
Disability Insurance (11)
|
—
|
|
|
—
|
|
|
180,000
|
|
|
—
|
|
|
180,000
|
|
|||||
Total
|
$
|
2,712,666
|
|
|
$
|
3,328,751
|
|
|
$
|
327,248
|
|
|
$
|
4,070,745
|
|
|
$
|
2,578,751
|
|
(1)
|
The amounts in this column represent payments made in the event of the death of the executive either prior to, within two years or more than two years after a CiC, assuming a termination date of December 31, 2015. With respect to amounts shown in the AIP row, if the death of an executive occurred within two years of a CiC, this amount may change as it is the prorated amount of the executive's target bonus in the year of termination.
|
(2)
|
Pursuant to the terms of the ESP, an executive who elects to retire after attaining age 62 is entitled to the benefits in this column (less any disability insurance proceeds).
|
(3)
|
Pursuant to the terms of our ESP, if severance payments are deemed to trigger the excise tax imposed by IRC Section 4999, the executive would receive the greater net after tax benefit of either (1) payment of the excise tax or (2) a reduction to cash severance to the "safe harbor" level so as not to trigger the excise tax. In Mr. Fibig's case, payment of the excise tax results in the greater net after tax benefit to him.
|
(4)
|
This amount represents (i) for Mr. Fibig, 2.0x the greater of the average AIP award paid for performance in the three years preceding the year of the presumed December 31, 2015 termination (i.e., the three years ending December 31, 2014) (or averaged over the lesser number of years during which the executive was eligible for AIP awards) or the executive's target annual incentive under the AIP for 2015, prorated for the number of active days of employment with the Company during the performance period; (ii) for Messrs. Mirzayantz and Haeni and Mses. Chwat and Cornell, 1.5x the executive's target annual incentive under the AIP for 2015 prorated for the number of active days of employment with the Company during the performance period; (iii) for Mr. O'Leary, 1.0x the executive's target annual incentive under the AIP for 2015 prorated for the number of active days of employment with the Company during the performance period. This amount does not take into account any actual AIP amounts paid for 2015, which are set forth in the Non-Equity Incentive Plan Compensation column of the Summary Compensation Table.
|
(5)
|
For Mr. O'Leary, this amount represents 1.5x, for Messrs. Mirzayantz and Haeni and Mses. Chwat and Cornell 2.0x, and Mr. Fibig 3.0x the greater of: (i) the average AIP award paid for performance in the three years preceding the year of the presumed December 31, 2015 termination (i.e., the three years ending December 31, 2014) (or averaged over the lesser number of years during which the executive was eligible for AIP awards); or (ii) the executive's target annual incentive under the AIP for 2015. This amount does not take into account any actual AIP amounts paid for 2015, which are set forth in the Non-Equity Incentive Plan Compensation column of the Summary Compensation Table.
|
(6)
|
The amounts in this row are the additional LTIP amounts that would be payable as severance with respect to the 2014-2016 and 2015-2017 LTIP cycles that would be paid in cash, based on prorated target LTIP for the relevant LTIP cycles in progress. Prorated amounts are based on the number of days worked in each performance period divided by the total number of days in each performance period for each relevant LTIP cycle. This amount does not take into account the actual amounts paid out under the completed 2013-2015 LTIP cycle, which are discussed in the narrative following the Grants of Plan-Based Award Table under the heading "Long-Term Incentive Plan."
|
(7)
|
For termination due to death or disability more than two years prior to a CiC, the amounts in this row represent the aggregate value of RSU and PRS awards which would immediately vest upon occurrence of the termination event. For termination events within two years after a CiC, the amounts in this row represent the aggregate in-the-money value of the options, SSARs, RSUs, PRS and other equity awards which would become vested as a direct result of the CiC before the stated vesting date specified in the applicable equity award document. The calculation of these amounts does not attribute any additional value to options based on their remaining exercise term and does not discount the value of awards based on the portion of the vesting period elapsed at the date of the CiC. These amounts also do not include any value for equity awards that, by their terms, are not accelerated and continue to vest.
|
(8)
|
Amounts in this row are the COBRA costs of medical and dental benefits for the covered period based on assumptions used for financial reporting purposes. Although our medical and dental insurance is generally available to our employees, only participants in our ESP, including our NEOs, would be entitled to have the benefits paid for by our Company.
|
(9)
|
The amounts in this row are the amounts that would be payable under our Executive Death Benefit Plan upon the death of the NEO.
|
(10)
|
The amounts in this row are the costs that we would incur to continue the Executive Death Benefit Plan for the NEO.
|
(11)
|
The amounts in this row are the amounts that would be payable under our disability insurance program upon the NEO's separation from employment due to long-term disability. This program is generally available to salaried employees.
|
REVENUE GROWTH
|
||||||
|
|
|
|
|
|
|
|
2013
|
|
2014
|
|
2015
|
|
Total Company
|
|
|
|
|
|
|
Reported Sales Growth
|
5%
|
|
5%
|
|
-2%
|
|
Currency Impact
|
0%
|
|
0%
|
|
7%
|
|
Currency Neutral Sales Growth
|
5%
|
|
5%
|
|
5%
|
|
|
|
|
|
|
|
|
ADJUSTED OPERATING PROFIT
|
||||||
|
|
|
|
|
|
|
(IN THOUSANDS U.S. $)
|
2013
|
|
2014
|
|
2015
|
|
Total Company
|
|
|
|
|
|
|
As Reported Operating Profit
|
516,339
|
|
592,321
|
|
588,347
|
|
Restructuring and Other Charges
|
7,401
|
|
6,398
|
|
7,594
|
|
Operational Improvement Initiative Costs
|
3,672
|
|
2,541
|
|
1,115
|
|
Spanish Tax Charges
|
13,011
|
|
—
|
|
—
|
|
Accelerated Contingent Consideration
|
—
|
|
—
|
|
7,192
|
|
Acquisition Related Costs
|
—
|
|
—
|
|
18,342
|
|
Spanish Capital Tax Charge Reversal
|
—
|
|
—
|
|
(10,530)
|
|
Adjusted Operating Profit
|
540,423
|
|
601,260
|
|
612,060
|
|
ADJUSTED EARNINGS PER SHARE (EPS)
|
||||||
|
|
|
|
|
|
|
(IN U.S. $)
|
2013
|
|
2014
|
|
2015
|
|
Total Company
|
|
|
|
|
|
|
As Reported EPS
|
4.29
|
|
5.06
|
|
5.16
|
|
Restructuring and Other Charges Tax Benefit
|
0.06
|
|
0.05
|
|
0.07
|
|
Operational Improvement Initiative Costs
|
0.03
|
|
0.02
|
|
0.01
|
|
Spanish Tax Charges
|
0.19
|
|
(0.05)
|
|
—
|
|
Accelerated Contingent Consideration
|
—
|
|
—
|
|
0.09
|
|
Acquisition Related Costs
|
—
|
|
—
|
|
0.15
|
|
Tax Settlement
|
—
|
|
—
|
|
(0.13)
|
|
Gain on Asset Sale
|
(0.10)
|
|
—
|
|
—
|
|
Spanish Capital Tax Charge Reversal
|
—
|
|
—
|
|
(0.09)
|
|
Adjusted EPS
|
4.46
1
|
|
5.08
|
|
5.25
1
|
|
|
|
|
|
|
|
|
1
The sum of the 2013 and 2015 adjusted EPS does not foot due to rounding.
|
![]()
INTERNATIONAL FLAVORS & FRAGRANCES INC.
521 WEST 57TH STREET
NEW YORK, NY 10019
|
|
VOTE BY INTERNET -
www.proxyvote.com
Use the internet to transmit your voting instructions up until the date and time indicated on the reverse side. Have your proxy card in hand when you access the web site and follow the instructions.
ELECTRONIC DELIVERY OF FUTURE SHAREHOLDER COMMUNICATIONS
If you would like to reduce the costs incurred by International Flavors & Fragrances Inc. in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive shareholder communications electronically in future years.
VOTE BY PHONE - 1-800-690-6903
Use any touch-tone telephone to transmit your voting instructions up until the date and time indicated on the reverse side. Have your proxy card in hand when you call and then follow the instructions.
VOTE BY MAIL
Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717, by the date and time indicated on the reverse side.
VOTE IN PERSON
You may vote the shares in person by attending the Annual Meeting.
|
TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:
|
|
E03614-P76126 KEEP THIS PORTION FOR YOUR RECORDS
|
||
|
|
|
|
|
|
|
|
|
|
DETACH AND RETURN THIS PORTION ONLY
|
|
INTERNATIONAL FLAVORS & FRAGRANCES INC.
|
|
|
|
|
|
|
||||||
|
|
The Board of Directors recommends you vote FOR Proposals 1, 2, and 3.
|
|
|
|
|
|
|
|||||
|
|
1.
Election of Directors
|
|
|
|
|
|
|
|
|
|
||
|
|
|
Nominees:
|
For
|
Against
|
Abstain
|
|
|
For
|
Against
|
Abstain
|
|
|
|
|
|
1a.
|
Marcello V. Bottoli
|
o
|
o
|
o
|
2.
|
To ratify the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2016.
|
o
|
o
|
o
|
|
|
|
|
1b.
|
Dr. Linda Buck
|
o
|
o
|
o
|
|
|
|
|
|
|
|
|
|
1c.
|
Michael L. Ducker
|
o
|
o
|
o
|
3.
|
Advisory vote to approve the compensation paid to the Company’s named executive officers in 2015.
|
o
|
o
|
o
|
|
|
|
|
1d.
|
David R. Epstein
|
o
|
o
|
o
|
|
|
|
|
|
|
|
|
|
1e.
|
Roger W. Ferguson, Jr.
|
o
|
o
|
o
|
|
|
|
|
|
|
|
|
|
1f.
|
John F. Ferraro
|
o
|
o
|
o
|
|
|
|
|
|
|
|
|
|
1g.
|
Andreas Fibig
|
o
|
o
|
o
|
|
|
|
|
|
|
|
|
|
1h.
|
Christina Gold
|
o
|
o
|
o
|
NOTE:
Such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
|
||||
|
|
|
1i.
|
Henry W. Howell, Jr.
|
o
|
o
|
o
|
|
|||||
|
|
|
1j.
|
Katherine M. Hudson
|
o
|
o
|
o
|
|
|
|
|
|
|
|
|
|
1k.
|
Dale F. Morrison
|
o
|
o
|
o
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For address changes and/or comments, please check this box and write them on the back where indicated.
|
|
|
o
|
|
|
|
|
|
|
|
|
|
|
Please indicate if you plan to attend this meeting.
|
o
|
o
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Yes
|
No
|
|
|
|
|
Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, trustee or guardian, please add your title as such. When signing as joint tenants, all parties in the joint tenancy must sign. If signer is a corporation or partnership, please sign in full corporate or partnership name by duly authorized officer.
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature [PLEASE SIGN WITHIN BOX]
|
Date
|
|
|
Signature (Joint Owners)
|
|
Date
|
|
|
ADMISSION TICKET
INTERNATIONAL FLAVORS & FRAGRANCES INC.
ANNUAL MEETING OF SHAREHOLDERS
MAY 2, 2016 AT 3:00 P.M. LOCAL TIME/9:00 A.M. EASTERN DAYLIGHT TIME
INTERNATIONAL FLAVORS & FRAGRANCES INC.
61 RUE DE VILLIERS
NEUILLY-SUR-SEINE, FRANCE
ADMITS ONE SHAREHOLDER
|
Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:
The Notice and Proxy Statement, Annual Report and Form 10-K are available at www.proxyvote.com.
|
||
|
|
|
|
|
|
|
|
|
|
E03615-P76126
|
|||
|
|
INTERNATIONAL FLAVORS & FRAGRANCES INC.
THIS PROXY CARD/VOTING INSTRUCTION FORM IS SOLICITED
ON BEHALF OF THE BOARD OF DIRECTORS
ANNUAL MEETING OF SHAREHOLDERS
MAY 2, 2016
The undersigned hereby appoint(s) each of Mr. Andreas Fibig, Ms. Alison A. Cornell and Ms. Anne Chwat as the attorney and proxy of the undersigned, with full power of substitution, to vote the number of shares of stock the undersigned is entitled to vote at the Annual Meeting of Shareholders of International Flavors & Fragrances Inc. to be held at 61 rue de Villiers, Neuilly-sur-Seine, France on Monday, May 2, 2016 at 3:00 P.M. Local Time/9:00 A.M. Eastern Daylight Time, and any adjournment(s) or postponement(s) thereof (the “Meeting”).
IF YOU ARE A SHAREHOLDER OF RECORD, THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED BY THE UNDERSIGNED ON THE REVERSE SIDE. IF NO SUCH DIRECTION IS MADE, THIS PROXY WILL BE VOTED FOR THE ELECTION OF ALL NOMINEES FOR DIRECTOR, FOR ITEMS 2 AND 3 AND ACCORDING TO THE DISCRETION OF THE PROXY HOLDERS ON ANY OTHER MATTER THAT MAY PROPERLY COME BEFORE THE MEETING. VOTING INSTRUCTIONS MUST BE RECEIVED BY 11:59 P.M. EASTERN DAYLIGHT TIME ON MAY 1, 2016.
If you are a participant in the International Flavors & Fragrances Inc. Retirement Investment Fund Plans (the “401(k) Plans”), this proxy covers all shares for which the undersigned has the right to give voting instructions to Vanguard Fiduciary Trust Company, the trustee of the 401(k) Plans. This proxy, when properly executed, will be voted as directed by the undersigned on the reverse side. Shares in the 401(k) Plans for which voting instructions are not received by 11:59 P.M. Eastern Daylight Time on April 28, 2016, or if no choice is specified, will be voted by the trustee in the same proportion as the shares for which voting instructions are received from other participants in the applicable 401(k) Plan.
PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY CARD/VOTING INSTRUCTION FORM PROMPTLY USING THE
ENCLOSED REPLY ENVELOPE.
|
|
||||
|
|
Address Changes/Comments:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
(If you noted any Address Changes/Comments above, please mark corresponding box on the reverse side.)
|
|
|||||
|
|
|
|
|
|
|
|
|
CONTINUED AND TO BE SIGNED ON REVERSE SIDE
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
Customers
Customer name | Ticker |
---|---|
The Estée Lauder Companies Inc. | EL |
L Brands, Inc. | LB |
Revlon, Inc. | REV |
Suppliers
Supplier name | Ticker |
---|---|
Stepan Company | SCL |
Sensient Technologies Corporation | SXT |
Tredegar Corporation | TG |
Flotek Industries, Inc. | FTK |
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|